Feedback detection for therapeutic equipment
By utilizing an EMR-based treatment system with a high numerical aperture optical system and plasma detection technology, the issues of precise positioning and safety in the treatment of dermal melasma have been resolved, enabling effective treatment and safe monitoring of dermal melasma.
Patent Information
- Application Number
- CN202211363487.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-22
- Filing Date
- 2019-06-20
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-06-20
AI Technical Summary
Current technologies are insufficient to effectively treat dermal melasma. Conventional skin rejuvenation treatments are effective on the epidermis but not on the dermis, and laser treatments may cause external skin damage and excessive or insufficient pigmentation. There is a lack of safe and effective treatment methods.
The treatment system employs EMR-based technology, which uses a high numerical aperture optical system to focus light energy to the dermis. Combined with plasma detection and imaging technology, it ensures precise positioning of the focal area and monitoring of treatment effects. This includes focusing optics, detectors, controllers, and windows to detect plasma characteristics in real time and adjust treatment parameters.
It enables precise treatment of dermal melasma, reduces damage to the epidermis, improves the safety and effectiveness of treatment, and provides real-time monitoring and recording of treatment results.
Smart Images

Figure CN115670643B_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with international application number PCT / US2019 / 038348, international application date June 20, 2019, date of entry into the Chinese national phase on February 19, 2021, national application number 201980054696.7, and invention name “Feedback detection for therapeutic devices”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 688,940, filed on June 22, 2018, entitled “Pigment Detection for Therapeutic Devices,” U.S. Provisional Patent Application No. 62 / 688,913, filed on June 22, 2018, entitled “Diffractive Optics for EMR-Based Tissue Therapy,” and U.S. Provisional Patent Application No. 62 / 688,855, filed on June 22, 2018, entitled “Selective Plasma Generation for Tissue Therapy.” Each of these applications is incorporated herein by reference in its entirety. Background Art
[0004] Melasma or chloasma (pregnancy face spot) is a common skin condition characterized by tan to dark grey-brown, irregular, well-defined spots and plaques on the face. Spots are considered to be caused by excessive production of melanin, which is absorbed by keratinocytes (epidermal melanosis) or deposited in the dermis (dermal melanosis, melanophages). The pigmented appearance of melasma can be aggravated by certain conditions (such as pregnancy, sun exposure, certain drugs (e.g. oral contraceptives), hormone levels and heredity). Conditions can be classified as epidermal, dermal or mixed according to the location of excess melanin. The typical symptoms of melasma mainly include dark, irregularly shaped patches or spots, which are common on the upper cheek, nose, upper lip and forehead. These patches usually develop gradually over time.
[0005] Melasma can cause considerable embarrassment and distress. This is particularly problematic for darker skin tones and women, affecting up to 30% of Southeast Asian women and many Latin American women. Based on population studies, only one-quarter to one-twentieth of affected individuals are male. According to the American Academy of Dermatology, approximately 6 million women in the United States deal with melasma. Globally, the number of people with melasma is estimated at 157 million in the Asia-Pacific region, 58 million in Latin America, and 3 million in Europe. Melasma usually appears between the ages of 20 and 40. Because there is no treatment for melasma, American patients who are treated for melasma currently try many different types of treatments. 79% of American patients try topical medications; while 37% use oral treatments; and 25% use lasers.
[0006] Unlike other pigmented structures that are usually present in the epidermal region of the skin (i.e., present at or near the tissue surface), dermal (or deep) dark spots are usually characterized by the widespread presence of melanin and melanophages in the underlying dermal portion. Therefore, since it is more difficult to approach and affect such pigmented cells and structures located deep in the skin, the treatment of dermal dark spots (e.g., fading the appearance of darkened pigmented areas) may be particularly challenging. Therefore, conventional skin rejuvenation treatments that mainly affect the upper epidermis (and are usually the first course of treatment for dark spots) (such as facial peeling (laser or chemical), dermabrasion, topical preparations, etc.) may be ineffective in treating dermal dark spots.
[0007] In addition, up to 50% of patients with melasma also experience other hyperpigmentation problems. Of all pigmentary diseases, melasma accounts for the largest proportion of patients likely to visit a dermatologist. Management of this disease remains challenging given the incomplete understanding of the pathogenesis, its chronicity, and recurrence rate. After treatment, melasma may recur, often worse than before treatment. Furthermore, topical treatments that work in treating epidermal melasma fail to effectively treat dermal or mixed melasma. Summary of the invention
[0008] It has been observed that the application of light or light energy to certain wavelengths can be strongly absorbed by pigmented cells, thereby damaging these pigmented cells. However, using light energy to effectively treat dermal dark spots has introduced several obstacles. For example, the pigmented cells in the dermis must be targeted with sufficient light energy of (multiple) appropriate wavelengths, to destroy or damage these pigmented cells, which can discharge or eliminate some pigmentations in pigmentation and reduce pigmentation appearance. However, such energy can be absorbed by the pigment (for example melanin) in the upper skin tissue (such as epidermis and upper dermis). This near-surface absorption can cause excessive damage to the outside part of the skin and insufficient transmission of energy to deeper dermis, thereby affecting pigmented cells therein. Moreover, the moderate thermal damage to the melanin-containing melanocytes in the basal layer of the epidermis can trigger the increase (for example hyperpigmentation) of melanin production, and the minimization (for example hypopigmentation) of melanin production can be triggered to the severe thermal damage of melanocytes.
[0009] The Pigmentary Diseases Association (PDA) evaluated the clinical effectiveness of different types of melasma treatments in an attempt to reach a consensus on treatment. Their findings were published in a paper by M. Rendon et al. entitled "Treatment of Melasma" published in the May 2006 Journal of the American Academy of Dermatology by Rendon et al., which reviewed the previous 20 years of literature related to melasma treatment and made determinations based on their review. Rendon et al. determined that "the panel consensus is that first-line therapy for melasma should consist of effective topical therapies (primarily fixed triple combinations)". Also, Rendon et al. determined that "lasers should be used sparingly in the treatment of melasma and, if used, should be considered based on skin type".
[0010] A criticism of Rendon et al.’s comprehensive report on melasma treatment could be that it is outdated, as it was published in 2006. A more recent article by M. Sadeghpour et al., published in 2018 in Advances in Aesthetic Surgery, entitled “Advances in the Treatment of Melasma,” sought to review current melasma treatment modalities. Sadeghpour et al. similarly concluded that “topical therapy using broad-spectrum sunscreen and 4% hydroquinone cream, tretinoin, or triple combination creams remains the gold standard for first-line therapy for melasma.” Sadeghpour et al. note that dermal melasma are more difficult to treat “because the destruction of these melanosomes is often accompanied by significant inflammation, which in turn stimulates the production of other melanogens.”
[0011] Therefore, there is a large unmet need for more effective and safe treatments for melasma and other difficult-to-treat pigmentary diseases.
[0012] Methods involving the application of light energy to small, discrete treatment locations in the skin that are separated by healthy tissue to promote healing have been developed. It may be challenging to accurately target a treatment location (e.g., located in the dermis) with desired specificity while avoiding damage to healthy tissue surrounding the treatment location (e.g., in the epidermis). For example, this requires an optical system with a high numerical aperture (NA) for focusing the laser beam to the treatment location. The high NA optical system delivers a sufficiently high focused flux (i.e., energy density) to the dermis while maintaining a sufficiently low defocus flux in the epidermis. U.S. Patent Application Publication No. 2016 / 0199132, entitled "Methods and Devices for Treating Dermal Black Spots," has shown that the technology is advantageous for treating dermal pigmentation including black spots in a research setting.
[0013] However, the technology requires that the focal area formed by the high NA optical system be precisely positioned (e.g., within a tolerance of about + / - 25 μm) at a depth within the target tissue. For example, melanocytes are typically located in the basal layer of the epidermis at a depth of about 100 μm. Dermal melanophages responsible for deep dark spots can be present in the upper dermis just below the basal layer of the epidermis (e.g., below 50 μm). Therefore, a difference in focal area depth of tens of microns can be the difference between effectively treating dermal pigmentation and inadvertently damaging melanocytes and potentially causing debilitating cosmetic effects (e.g., hypopigmentation). Partly for this reason, EMR-based systems that effectively treat dermal pigmentation are not yet commercially available.
[0014] Therefore, there is a need to develop an EMR-based treatment system that reliably positions a focal region at a specified depth within a tolerance of tens of microns (e.g., about ±100 μm, about ±10 μm, about ±1 μm, etc.). Further, it may be desirable for the EMR-based treatment system to achieve this performance in part through calibration (e.g., by periodically placing the focal region at a reference having a known depth). In addition, it may be desirable to use the reference used during calibration during treatment. For example, the reference may include an interface that establishes robust contact with and stabilizes the treatment region.
[0015] Some methods developed for dermal pigmentation treatment (such as those outlined by Anderson et al.) may employ selective thermal plasma generation as a therapeutic approach. In these cases, the laser fluence at the focal region within the dermis is above the thermal plasma threshold (e.g., 10 9 W / cm 2 ), but below the optical breakdown threshold (e.g. 10 12 W / cm 2 ). This selectively causes plasma formation when the focal area is located at pigmented tissue (e.g., melanin) within the dermis, but does not generate plasma in non-pigmented tissue in the dermis or pigmented epidermal tissue above the focal area. The selectively formed hot ionic plasma destroys or damages the pigment and surrounding tissue. This destruction ultimately leads to the removal of dermal pigment. Therefore, in some embodiments, the presence of plasma in the treated tissue during treatment can indicate effective treatment. Since the selection of parameters for laser-based skin treatments typically depends on the skin type and therefore on each individual patient, the presence of plasma can be used as an indication that the correct treatment parameters have been reached. Therefore, this feedback is desirable for the successful treatment of conditions (such as dark spots) in populations that are typically underserved by laser-based treatments (e.g., populations with dark skin types).
[0016] Alternatively, in some cases, the characteristics of the detected plasma can indicate that the treatment has an adverse effect. For example, in some embodiments, a transmission window is placed on the skin being treated to reference the skin and prevent it from moving during treatment. When the laser beam etches the window, the treatment may fail. The etching of the window prevents further effective transmission of the laser to the tissue and often coincides with very bright plasma formation in the window itself. If treatment is continued with the etched window, the heat accumulation in the window will likely damage the epidermis of the skin (e.g., burns and blistering). Therefore, it is advantageous to use feedback to detect plasma formation in the window and stop treatment when it occurs.
[0017] Based on the foregoing, it can be understood that plasma formation during treatment can be both beneficial and detrimental to the treatment. Therefore, systems and methods for providing plasma detection can continuously detect the characteristics of plasma in real time and distinguish between plasma that is beneficial to tissue treatment and plasma that is detrimental to tissue treatment.
[0018] In some embodiments, it may be desirable to image the tissue being treated from the perspective of the treatment device and project that view onto a screen for viewing by a medical practitioner. In one aspect, placement of the treatment device typically obscures the medical practitioner's view of the tissue being treated. Thus, tissue imaging can aid in accurate placement of the treatment device for targeting the affected tissue. Additionally, since the goal of treatment for many pigmentary conditions is aesthetics (e.g., improving skin appearance), images of the skin can be consistently acquired under repeatable imaging conditions (e.g., lighting and distance) during imaging so that the effectiveness of the treatment can be ascertained.
[0019] People with pigmentary conditions, such as melasma, have long desired widespread use of EMR-based treatments for their conditions. Accordingly, as discussed in more detail below, an EMR-based treatment system is provided that provides repeatable deep localization of a focal area within a target tissue. The disclosed systems and methods can also detect and record plasma events to document and track treatment safety and effectiveness, and image the treated tissue to accurately deliver EMR to the treatment area. These capabilities solve many technical problems that currently prevent widespread successful treatment of dermal pigmentation and other difficult-to-treat skin conditions using EMR-based systems.
[0020] In one embodiment, a system is provided. The system may include: focusing optics, a detector, a controller, and a window. The focusing optics may be configured to converge an electromagnetic radiation (EMR) beam to a focal region positioned along an optical axis. The detector may be configured to detect signal radiation emitted from a predetermined position along the optical axis. The controller may be configured as a controller that adjusts parameters of the EMR beam based in part on the signal radiation detected by the detector. The window may be positioned along the optical axis between the focal region and the focusing optics at a predetermined depth away from the focal region. The window may be configured to contact a surface of the tissue.
[0021] In another embodiment, the EMR beam may be configured to generate a plasma at a predetermined location along the optical axis.Signal radiation may be emitted from the plasma.
[0022] In another embodiment, signal radiation may emanate from the interaction between the EMR beam and the window.
[0023] In another embodiment, the focusing optics may also be configured to image the signal radiation detected by the detector.
[0024] In another embodiment, the system may further include: a scanner configured to scan the focus region from a first region within the tissue to a second region within the tissue.
[0025] In another embodiment, the EMR beam may also be configured to generate a thermionic plasma at the focal region.
[0026] In another embodiment, the window may also be configured to transmit the EMR beam.
[0027] In another embodiment, the focusing optics may be further configured to focus the EMR beam with a numerical aperture (NA) of at least 0.3.
[0028] In another embodiment, the parameters of the EMR beam may include at least one of: pulse energy, repetition rate, pulse duration, focal region position, focal region size, wavelength, or power.
[0029] In another embodiment, the signal radiation may include at least one of: visible light, infrared light, an acoustic signal, an ultrasonic signal, a radio signal, or temperature.
[0030] In one embodiment, a method is provided. The method may include contacting a surface of tissue using a window. The method may also include converging an electromagnetic radiation (EMR) beam to a focal region positioned along an optical axis using focusing optics. The method may also include detecting signal radiation emitted from a position along the optical axis using a detector. The method may additionally include adjusting parameters of the EMR beam based in part on the detected signal radiation using a controller. The method may also include positioning the focal region within the tissue at a predetermined distance from the surface of the tissue.
[0031] In another embodiment, the method may further include: generating a plasma at a location along the optical axis using the EMR beam.The signal radiation may be emitted from the plasma.
[0032] In another embodiment, the method may further include directing the converging EMR beam incident on the window.Signal radiation may emanate from the interaction between the EMR beam and the window.
[0033] In another embodiment, the method further comprises imaging the signal radiation incident on the detector using focusing optics.
[0034] In another embodiment, the method further comprises scanning the focal region from a first region within the tissue to a second region within the tissue using a scanner.
[0035] In another embodiment, the method further includes generating a thermal ionic plasma at the focal region using the EMR beam.
[0036] In another embodiment, the method further comprises transmitting the EMR beam through the window.
[0037] In another embodiment, the focusing optics are further configured to focus the EMR beam with a numerical aperture (NA) of at least 0.3.
[0038] In another embodiment, the parameters of the EMR beam may include at least one of: pulse energy, repetition rate, pulse duration, focal region position, focal region size, wavelength, or power.
[0039] In another embodiment, the signal radiation includes at least one of: visible light, infrared light, an acoustic signal, an ultrasonic signal, a radio signal, or temperature.
[0040] In one embodiment, a system is provided. The system may include: focusing optics, a window, an optical detector, a controller, and a stage. The focusing optics may be configured to focus an electromagnetic radiation (EMR) beam to a focal region positioned along an optical axis. The window may intersect the optical axis, and the window may be configured to contact a surface of a tissue. The optical detector may be configured to detect signal radiation emitted from an interaction of the EMR beam with the window. The controller may be configured to determine a reference position at which a portion of the focal region substantially coincides with a surface of the window. The stage may be configured to translate the focal region to a treatment position located at a predetermined distance from the reference position.
[0041] In another embodiment, the focusing optics and stage may be configured to locate a treatment location within tissue.
[0042] In another embodiment, the treatment site may be located within the dermal tissue.
[0043] In another embodiment, the EMR beam may be configured to generate a thermionic plasma at the focal region.
[0044] In another embodiment, the EMR beam may include pulses having a pulse duration of at least 1 picosecond.
[0045] In another embodiment, the focusing optics may also be configured to image the signal radiation incident on the detector.
[0046] In another embodiment, the controller may be further configured to determine the reference position by determining a lateral width of the EMR beam at the surface of the entrance window based on the signal radiation and translating the focal region until the lateral width has a minimum value.
[0047] In another embodiment, the detector may be further configured to detect the intensity of the signal radiation, and the controller may be further configured to determine the reference position by translating the focus area until the intensity of the signal radiation has a maximum value.
[0048] In another embodiment, the focusing optics may be further configured to converge the second EMR beam to a second focal region. The second EMR beam may have at least one of the following: a wavelength that is the same as the wavelength of the EMR beam or a wavelength that is different from the wavelength of the EMR beam. The second EMR beam may be configured to produce a desired change in the tissue.
[0049] In another embodiment, the stage can be configured to translate the focal region by translating at least one of: focusing optics, one or more optical elements, and a window.
[0050] In one embodiment, a method is provided, comprising: converging an electromagnetic radiation (EMR) beam to a focal region positioned along an optical axis using focusing optics. The method may also include: detecting, using a detector, signal radiation emitted from an interaction of the EMR beam with a window intersecting the optical axis. The method may also include: determining, using a controller, a reference position along the optical axis based on the detected signal radiation. At the reference position, a portion of the focal region may substantially coincide with a surface of the window. The method may also include: translating the focal region to a treatment position located at a predetermined distance from the reference position.
[0051] In another embodiment, the method may further include contacting a surface of the tissue with the window so that the treatment location may be located within the tissue.
[0052] In another embodiment, the predetermined distance may be configured such that the treatment location is within the dermal tissue.
[0053] In another embodiment, the EMR beam may be configured to generate a thermionic plasma in the focal region.
[0054] In another embodiment, the EMR beam may include pulses having a pulse duration of at least 1 picosecond.
[0055] In another embodiment, detecting the signal radiation may further include imaging the signal radiation incident on the detector using focusing optics.
[0056] In another embodiment, determining the reference position may further include: determining, using a controller, a lateral width of the EMR beam at a surface of the entrance window based on the signal radiation; and translating the focal region along the optical axis until the lateral width has a minimum value.
[0057] In another embodiment, determining the reference position may further include: detecting the intensity of the signal radiation using a detector; and translating the focus area until the intensity of the signal radiation has a maximum value.
[0058] In another embodiment, the method may further include: converging the second EMR beam to a second focal region using focusing optics. The second EMR beam may have at least one of: a wavelength that is the same as the wavelength of the EMR beam or a wavelength that is different from the wavelength of the EMR beam. The second EMR beam may be configured to produce a desired change in the tissue.
[0059] In another embodiment, translating the focal region may further include translating at least one of: a focusing optic, one or more optical elements, and a window.
[0060] In one embodiment, a system is provided and may include: a radiation source, a window, a focusing optical device, a scanner, a detector, and a controller. The radiation source may be configured to generate therapeutic radiation configured to produce a desired change in tissue. The window may be configured to contact a surface of the tissue. The focusing optical device may be configured to focus therapeutic radiation configured to generate plasma at a focal region to the focal region. The scanner may be configured to scan the focal region. The detector may be configured to detect signal radiation emitted from the plasma. The controller may be configured to determine whether the plasma is at least partially within the window based on the detected signal radiation, and control one or more parameters of the therapeutic radiation based on the determination.
[0061] In another embodiment, the controller may be further configured to determine one or more characteristics of the plasma.
[0062] In another embodiment, the one or more characteristics of the plasma may include at least one of: presence of the plasma, intensity of the plasma, spectral content of the plasma, and location of the plasma.
[0063] In another embodiment, the controller may be further configured to terminate the therapeutic radiation based on the determination.
[0064] In another embodiment, the one or more parameters of the therapeutic radiation may include at least one of: energy per pulse, repetition rate, location of the focal region, and size of the focal region.
[0065] In another embodiment, the desired change in the tissue may include generating a selective thermionic plasma in the presence of a chromophore.
[0066] In another embodiment, the controller may be further configured to record characteristics of the signal radiation.
[0067] In another embodiment, the controller may be further configured to: record a first characteristic of a first signal radiation emitted from a first plasma at a first location; map the first characteristic to coordinates for the first location; record a second characteristic of a second signal radiation emitted from a second plasma at a second location; and map the second characteristic to coordinates for the second location.
[0068] In another embodiment, the controller may be further configured to determine whether the plasma is at least partially within the window based on the intensity of the signal radiation.
[0069] In another embodiment, the controller may be further configured to determine whether the plasma is at least partially within the window based on spectral components of the signal radiation.
[0070] In one embodiment, a method is provided. The method may include: generating, using a radiation source, therapeutic radiation configured to produce a desired change in tissue. The method may also include: contacting the surface of the tissue using a window. The method may also include: focusing the therapeutic radiation to a focal area using a focusing optical device. The method may additionally include: scanning the focal area using a scanner. The method may additionally include: generating a plasma at the focal area using the therapeutic radiation. The method may also include: detecting signal radiation emitted from the plasma using a detector. The method may additionally include: determining, using a controller, whether the plasma is at least partially within the window based on the detected signal radiation. The method may also include: controlling, using a controller, one or more parameters of the therapeutic radiation based on the determination.
[0071] In another embodiment, the method may further include determining, with the controller, one or more characteristics of the plasma.
[0072] In another embodiment, the one or more characteristics of the plasma may include at least one of: presence of the plasma, intensity of the plasma, spectral content of the plasma, and location of the plasma.
[0073] In another embodiment, the method may further include terminating, using the controller, the therapeutic radiation based on the determination.
[0074] In another embodiment, the one or more parameters of the therapeutic radiation may include at least one of: energy per pulse, repetition rate, location of the focal region, and size of the focal region.
[0075] In another embodiment, the desired change in the tissue may be the generation of a selective thermionic plasma in the presence of a chromophore.
[0076] In another embodiment, the method may include recording, with the controller, characteristics of the signal radiation.
[0077] In another embodiment, the method may further include: recording, using a controller, a first characteristic of a first signal radiation emitted from a first plasma at a first location; mapping the first characteristic to coordinates for the first location; recording, using a data acquisition device, a second characteristic of a second signal radiation emitted from a second plasma at a second location; and mapping the second characteristic to coordinates for the second location.
[0078] In another embodiment, determining whether the plasma is at least partially within the window may be based on the intensity of the signal radiation.
[0079] In another embodiment, determining whether the plasma is at least partially within the window may be based on spectral components of the signal radiation.
[0080] In one embodiment, a system is provided and may include: a radiation source, a focusing optic, a detector, and therapeutic radiation. The radiation source may be configured to illuminate tissue with imaging radiation. The focusing optic may be configured to image a view of the tissue. The detector may be configured to detect an image of the view of the tissue. The therapeutic radiation may be configured to be focused using the focusing optic to a focal region within a target treatment region specified based in part on the image.
[0081] The system may also include a scanner configured to scan the view to a second region of the tissue. The focusing optics may also be configured to image a second image of the view from the second region of the tissue. The detector may also be configured to detect the second image.
[0082] In another embodiment, the scanner may also be configured to scan a focal area within the target treatment area.
[0083] In another embodiment, the system may further include a controller configured to stitch the image and the second image into a map. The map may be configured to be used to determine at least one of: a diagnosis, a treatment plan, and a treatment parameter for therapeutic radiation.
[0084] In another embodiment, the system may further include a window configured to contact a surface of the tissue such that the focal region is located at a predetermined depth from the surface of the tissue.
[0085] In another embodiment, the system may further include a controller configured to record the image.
[0086] In another embodiment, the system may further include a controller configured to control parameters of the therapeutic radiation based in part on the image.
[0087] In another embodiment, the therapeutic radiation may be configured to selectively generate plasma at chromophores near the focal region.
[0088] In another embodiment, the focusing optical device may be further configured to image the first image using at least one of: microscopic imaging, wide field imaging, and reflective confocal imaging.
[0089] In another embodiment, the system may further include a display configured to display the image.
[0090] In one embodiment, a method is provided. The method may include: illuminating tissue with imaging radiation using a radiation source. The method may also include: imaging an image of a view of the tissue using focusing optics. The method may additionally include: detecting the image using a detector. The method may also include: specifying a target treatment region of the tissue based in part on the image. The method may also include: converging the treatment radiation to a focal region within the target treatment region using focusing optics.
[0091] In another embodiment, the method may further include: scanning the view to a second region of the tissue using a scanner; imaging a second image of the view from the second region of the tissue using focusing optics; and detecting the second image using a detector.
[0092] In another embodiment, the method may further include: scanning the focal area within the target treatment area using a scanner.
[0093] In another embodiment, the method may further include: stitching the image and the second image together into a map.
[0094] In another embodiment, the method may further include determining from the map at least one of: a diagnosis, a treatment plan, and treatment parameters for therapeutic radiation.
[0095] In another embodiment, the method may further include contacting a surface of the tissue with the window such that the focal region is located at a predetermined depth from the surface of the tissue.
[0096] In another embodiment, the method may further include: recording the image using the controller.
[0097] In another embodiment, the method may further include controlling, using the controller, parameters of the therapeutic radiation based in part on the image.
[0098] In another embodiment, the therapeutic radiation may be configured to selectively generate plasma at chromophores near the focal region.
[0099] In another embodiment, imaging the first image may include at least one of the following: microscopic imaging, wide-field imaging, or reflective confocal imaging.
[0100] In another embodiment, the method may further include: displaying the image using a display. BRIEF DESCRIPTION OF THE DRAWINGS
[0101] Embodiments of the present disclosure will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
[0102] Figure 1 illustrates an illustrative embodiment of a therapeutic system according to some embodiments;
[0103] Figure 2 is a schematic illustration of an electromagnetic radiation (EMR) beam being focused into a pigmented area of the dermis in the skin.
[0104] Figure 3A is an exemplary absorption spectrum diagram for melanin;
[0105] Figure 3B is an exemplary absorption spectrum diagram for hemoglobin;
[0106] Figure 4 A graph illustrating the absorption coefficient of melanin and venous blood and the scattering coefficient of light in the skin versus wavelength;
[0107] Figure 5 is a schematic illustration of a treatment system according to some embodiments;
[0108] Figure 6 is a schematic illustration of an optical system according to some embodiments;
[0109] Figure 7 is a schematic illustration of an optical system with a microscope attachment according to some embodiments;
[0110] Figure 8 is a schematic illustration of an optical system with a fiber coupler attachment according to some embodiments;
[0111] Fig. 9 illustrates a flow chart of a plasma detection method according to some embodiments;
[0112] Fig.10 illustrates a schematic diagram of a plasma detection system according to some embodiments;
[0113] Fig.11A is a schematic illustration of a therapeutic optical system according to some embodiments;
[0114] Fig. 11B The histology of a cross section of a skin sample with a melanin tattoo is shown;
[0115] Fig.12 illustrates spectra associated with radiation from plasma generated in a melanin tattoo and radiation from no plasma generated in clear skin, according to some embodiments;
[0116] Fig.13 illustrates spectra associated with radiation from plasma generated in a carbon tattoo and radiation from no plasma generated in clear skin, according to some embodiments;
[0117] Fig.14illustrates the spectrum of radiation generated by plasma in a skin sample according to some embodiments;
[0118] Fig.15 illustrates a spectrum of radiation from a plasma formed using a sapphire window according to some embodiments;
[0119] Fig.16A illustrates a front view of an illustrative version of a plasma detection system according to some embodiments;
[0120] Fig. 16B illustrates a cross-sectional view of an illustrative version of a plasma detection system according to some embodiments;
[0121] Fig. 16C illustrates a detail view of an illustrative version of a plasma detection system according to some embodiments;
[0122] Fig.17 illustrates a flow chart for window referencing according to some embodiments;
[0123] Fig.18A illustrates a schematic diagram of a window reference system according to some embodiments;
[0124] Fig.18B illustrates performance of a window reference system according to some embodiments;
[0125] Fig.19 illustrates an illustrative bench prototype for confocal imaging according to some embodiments;
[0126] Fig. 20 illustrates a maximum radiation intensity measure according to some embodiments;
[0127] Fig.21A illustrates a front view of an illustrative version of a therapeutic system without a removable window reference system attached, according to some embodiments;
[0128] Fig.21B illustrates a front view of an illustrative version of a therapeutic system with a removable window reference system attached, according to some embodiments;
[0129] Fig. 21C illustrates a cross-sectional view of an illustrative version of a therapeutic system with a removable window reference system attached, according to some embodiments;
[0130] Fig.22A illustrates a front view of an illustrative version of a treatment system without a window reference system attached, according to some embodiments;
[0131] Fig. 22Billustrates a front view of an illustrative version of a therapeutic system with a window reference system attached, according to some embodiments;
[0132] Fig. 22C illustrates a cross-sectional view of an illustrative version of a therapeutic system with a window reference system attached, according to some embodiments;
[0133] Fig.23 illustrates a flow chart of a method of imaging and radiation based therapy according to some embodiments;
[0134] Fig.24 illustrates a schematic diagram of an imaging and radiation based therapy system according to some embodiments;
[0135] Fig.25 schematically illustrates a stitched image according to some embodiments;
[0136] Fig.26A illustrates an elevation view of an illustrative version of an imaging and radiation based therapy system according to some embodiments;
[0137] Fig.26B illustrates an illustrative version of an imaging and radiation based therapy system according to some embodiments;
[0138] Fig.27A shows a black and white image taken using an illustrative version of an imaging and radiation based therapy system in accordance with some embodiments; and
[0139] Fig.27B Shown is a stitched black and white image including multiple images taken using an illustrative version of an imaging and radiation based therapy system, in accordance with some embodiments.
[0140] It should be noted that the drawings are not necessarily drawn to scale. The drawings are intended only to depict typical aspects of the subject matter disclosed herein and therefore should not be considered to limit the scope of the present disclosure. The systems, devices, and methods specifically described herein and illustrated in the accompanying drawings are non-limiting exemplary embodiments. DETAILED DESCRIPTION
[0141] Certain illustrative embodiments will now be described to provide an overall understanding of the principles of structure, function, manufacture and use of the apparatus and methods disclosed herein. One or more examples of these embodiments are illustrated in the accompanying drawings. It should be understood by those skilled in the art that the apparatus and methods specifically described herein and illustrated in the accompanying drawings are non-limiting illustrative embodiments, and the scope of the present invention is limited only by the claims. The features illustrated or described in conjunction with an illustrative embodiment may be combined with the features of other embodiments. Such modifications and variations are intended to be included within the scope of the present invention.
[0142] Embodiments of the present disclosure are discussed in detail below with respect to the treatment of pigmentary conditions of the skin, such as melasma, to improve the appearance of such pigmentary conditions. However, the disclosed embodiments may be used to treat other pigmentary conditions and non-pigmentary conditions and other tissue targets and non-tissue targets without limitation. Examples of pigmentary conditions may include, but are not limited to, post-inflammatory hyperpigmentation, dark skin around the glasses, dark eyes, coffee-colored patches, Becker's nevus, nevus of Ota, congenital melanocytic nevus, freckles (spots), and pigmented spots. Additional examples of pigmented tissues and structures that may be treated include, but are not limited to, structures rich in hemosiderin, pigmented gallstones, tissues containing tattoos, and structures rich in lutein, zeaxanthin, rhodopsin, carotenoid pigments, biliverdin, bilirubin, and hemoglobin. Examples of targets for treating non-pigmented structures, tissues, and conditions may include, but are not limited to, hair follicles, hair shafts, vascular lesions, infectious conditions, sebaceous glands, acne, and the like.
[0143] Methods for treating various skin conditions (such as for cosmetic purposes) can be performed using the systems described herein. It should be understood that although such methods can be performed by a physician, non-physicians (such as beauticians and other appropriately trained personnel) can use the systems described herein to treat various skin conditions without physician supervision.
[0144] Further, in the present disclosure, components of the same name of an embodiment generally have similar features, and therefore, within a particular embodiment, it is not necessary to fully elaborate on every feature of each component of the same name. In addition, to the extent that linear or circular dimensions are used in the description of the disclosed systems, devices, and methods, such dimensions are not intended to limit the types of shapes that can be used in conjunction with such systems, devices, and methods. It should be recognized by those skilled in the art that equivalents to such linear and circular dimensions can be easily determined for any geometric shape. The size and shape of the systems and devices and their components can depend at least on the anatomy of the subject in which the systems and devices will be used, the size and shape of the components with which the systems and devices will be used, and the methods and processes in which the systems and devices will be used.
[0145] In general, a high numerical aperture (NA) optical treatment system that can focus electromagnetic radiation (EMR) (e.g., a laser beam) to a treatment area in a tissue is described. Unless otherwise mentioned, the terms "EMR," "EMR beam," and "laser beam" are used interchangeably herein. The focused laser beam can deliver light energy to the treatment area without damaging surrounding tissue. The delivered light energy can, for example, destroy pigmented chromophores and / or targets in the treatment area of the dermis layer of the skin without affecting surrounding areas (e.g., the upper epidermis layer, other parts of the dermis layer, etc.). In other embodiments, the delivered light energy can cause tattoo removal or alteration or hemoglobin-related treatments.
[0146] Exemplary methods and apparatus for treating skin conditions using light or light energy are disclosed in U.S. Patent Application Publication No. 2016 / 0199132, entitled “Methods and Apparatus for Treating Dermal Dark Spots,” and U.S. Provisional Application No. 62 / 438,818, entitled “Methods and Apparatus for Selective Treatment of Dermal Dark Spots,” each of which is hereby incorporated by reference herein in its entirety.
[0147] In general, systems and corresponding methods for treating pigmented conditions in tissue are provided. As discussed in more detail below, the disclosed systems and methods employ electromagnetic radiation (EMR), such as a laser beam, to deliver a predetermined amount of energy to a target tissue. The EMR can be focused to a focal area, and the focal area can be translated or rotated in any direction relative to the target tissue. The predetermined amount of radiation can be configured to thermally destroy or otherwise damage a portion of the tissue exhibiting a pigmented condition. In this manner, a predetermined amount of energy can be delivered to any location within the target tissue to treat a pigmented condition, such as to improve its appearance.
[0148] Figure 1 An illustrative embodiment of a treatment system 10 is illustrated. As shown, the treatment system 10 includes a mounting platform 12, a transmitter 14, and a controller 16. The mounting platform 12 may include one or more manipulators or arms 20. The arm 20 may be coupled to the transmitter 14 to perform various treatments on a target tissue 22 of a subject 24. The operation of the mounting platform 12 and the transmitter 14 may be directed manually by a user or using the controller 16 (e.g., via a user interface). In some embodiments (not shown), the transmitter may have a handheld form factor and the mounting platform 12 may be omitted.
[0149] The transmitter 14 and the controller 16 (and optionally, the mounting platform 12) can communicate with each other via the communication link 26 according to any suitable communication protocol, which communication link 26 can be any suitable type of wired and / or wireless communication link carrying any suitable type of signal (e.g., electrical signals, optical signals, infrared signals, etc.).
[0150] Embodiments of the controller 16 may be configured to control the operation of the emitter 14. In one aspect, the controller 16 may control the movement of the EMR 30. As discussed in detail below, the emitter 14 may include a source 32 for emitting the EMR 30 and a scanning system 34 for manipulating the EMR 30. As an example, the scanning system 34 may be configured to focus the EMR 30 to a focal region and to translate and / or rotate the focal region in space. The controller 16 may send a signal to the source 32 via the communication link 26 to command the source 32 to emit EMR 30 having one or more selected characteristics, such as wavelength, power, repetition rate, pulse duration, pulse energy, focusing characteristics (e.g., focal volume, Raleigh length, etc.). In another aspect, the controller 16 may send a signal to the scanning system 34 via the communication link 26 to command the scanning system 34 to move the focal region of the EMR 30 relative to the target tissue 22 using one or more translation and / or rotation operations.
[0151] Embodiments of the treatment system 10 and method are discussed herein in the context of targets within skin tissue, such as the dermis. However, the disclosed embodiments may be used to treat any tissue in any location of a subject without limitation. Examples of non-skin tissue may include, but are not limited to, mucosal tissue, genital tissue, visceral organ tissue, and surface and subsurface regions of gastrointestinal tissue.
[0152] Figure 2It is a schematic diagram of a laser beam focused in a pigmented area of the dermis layer in the skin tissue. The skin tissue includes a skin surface 100 and an upper epidermis layer 110 or epidermis, and its thickness in the facial area can be, for example, about 30 μm to 120 μm. The epidermis 110 can be slightly thicker in other parts of the body. For example, in general, the thickness of the epidermis can range from about 30 μm (for example, with respect to the eyelid) to about 1500 μm (for example, with respect to the palm or the sole of the foot). In some skin conditions (such as psoriasis), such an epidermis can be thinner or thicker than the above examples. The underlying dermis layer 120 or dermis extends from below the epidermis 110 to a deeper subcutaneous fat layer (not shown). The skin showing deep or dermal dark spots can include a group of pigmented cells or regions 130 containing excessive melanin. Electromagnetic radiation (EMR) 150 (such as a laser beam) can be focused to one or more focal areas 160 that can be located in the dermis 120 or epidermis 110. EMR 150 may be provided at one or more suitable wavelengths absorbable by melanin. The EMR wavelength(s) may be selected based on one or more criteria described below.
[0153] Properties of therapeutic radiation
[0154] Determination of the desired wavelength for treating certain skin conditions (such as pigmented conditions and non-pigmented conditions) can depend on, for example, the wavelength-dependent absorption coefficients of various competing chromophores present in the skin (e.g., chromophores, hemoglobin, tattoo ink, etc.). Figure 3A is an exemplary absorption spectrum of melanin. It is observed that the absorption of EMR by melanin reaches a peak at a wavelength of about 350 nm and then decreases as the wavelength increases. Although the absorption of EMR by melanin promotes heating and / or destruction of the region 130 containing melanin, very high melanin absorption can cause high absorption of the pigment in the epidermis 110 and reduced penetration of EMR into the dermis 120 or epidermis 110. Figure 3A As shown in FIG. 1 , melanin absorption is relatively high at EMR wavelengths less than about 500 nm. Therefore, wavelengths less than about 500 nm may not be suitable for sufficiently penetrating into the dermis 120 to heat and damage or destroy the pigmented regions 130 therein. This enhanced absorption at smaller wavelengths can result in excess damage to the upper (surface) portions of the epidermis 110 and dermis 120, where relatively less unabsorbed EMR passes through the tissue into deeper portions of the dermis 120.
[0155] Figure 3B is an exemplary absorption spectrum of oxidized or deoxygenated hemoglobin. Hemoglobin is present in the blood vessels of skin tissue and can be oxidized (HbO2) or deoxygenated (Hb). Each form of hemoglobin can exhibit slightly different EMR absorption characteristics. Figure 3B, the exemplary absorption spectra of both Hb and HbO2 indicate high absorption coefficients for both Hb and HbO2 at EMR wavelengths less than about 600 nm, with absorption decreasing significantly at higher wavelengths. Strong absorption of EMR directed into skin tissue by hemoglobin (Hb and / or HbO2) can result in heating of blood vessels containing hemoglobin, thereby causing unnecessary damage to these vascular structures and less EMR available for melanin absorption when the desired treatment is melanin-rich tissue or structure.
[0156] Selecting an appropriate wavelength for EMR may also depend on the wavelength-dependent scattering profile of the tissue with which the EMR interacts. Figure 4 Shown is a graph of the absorption coefficient of melanin and venous (deoxygenated) blood versus wavelength. Figure 4 A graph of the scattering coefficient of light in the skin versus wavelength is also illustrated. The absorption of melanin decreases monotonically with wavelength. If melanin is the target for treatment of pigmentary conditions, wavelengths with high absorption in melanin are desirable. This would indicate that the shorter the wavelength of light, the more efficient the treatment. However, absorption by blood increases at wavelengths shorter than 800nm, increasing the risk of inadvertently targeting blood vessels. In addition, since the intended target may be located below the surface of the skin, the scattering effect of the skin (e.g., dermis) may be significant. Scattering reduces the amount of light that reaches the intended target. The scattering coefficient decreases monotonically with increasing wavelength. Therefore, while shorter wavelengths may be beneficial for absorption of melanin, longer wavelengths may be beneficial for deeper penetration due to reduced scattering. Similarly, since blood absorption is lower at longer wavelengths, longer wavelengths are more beneficial for avoiding blood vessels.
[0157] In view of the above considerations, wavelengths ranging from about 400nm to about 4000nm, and more specifically, from about 500nm to about 2500nm, can be used to selectively target certain structures (e.g., melanin) in the dermis. Specifically, wavelengths of about 800nm and about 1064nm can be useful for such treatments. The wavelength of 800nm can be attractive because of the low cost and easy availability of laser diodes at this wavelength. However, 1064nm can be particularly useful for targeting deeper lesions due to the lower scattering at this wavelength. The wavelength of 1064nm can also be more suitable for dark skin types with a large amount of epidermal melanin. In such individuals, the higher absorption of lower wavelength EMR (e.g., about 800nm) by melanin in the epidermis increases the chance of thermal damage to the skin. Therefore, 1064nm can be a more suitable wavelength for therapeutic radiation for certain treatments of some individuals.
[0158] Various laser sources can be used to generate EMR. For example, a neodymium (Nd) laser source can be easily obtained, which provides an EMR of 1064nm. These laser sources can be operated in a pulsed mode, wherein the repetition rate is in the range of about 1Hz to 100KHz. A Q-switched Nd laser source can provide laser pulses with a pulse duration less than one nanosecond. Other Nd laser sources can provide pulses with a pulse duration of more than one millisecond. An exemplary laser source providing 1060nm wavelength EMR is a 20W NuQ fiber laser from Nufern, East Granby, Connecticut, USA. The 20W NuQ fiber laser provides a pulse with a pulse duration of about 100ns at a repetition rate in the range between about 20KHz and about 100KHz. Another laser source is a Nd:YAG Q-smart 850 from Quantel, Les Sulis, France. Q-smart 850 provides pulses with a pulse energy of up to about 850mJ and a pulse duration of about 6ns at a repetition rate of up to about 10Hz.
[0159] The systems described herein can be configured to focus the EMR in a highly convergent beam. For example, the system can include a focusing or converging lens arrangement having a numerical aperture (NA) selected from about 0.3 to 1 (e.g., between about 0.5 and about 0.9). The correspondingly large convergence angle of the EMR can provide high flux and intensity in the focal region of the lens (which can be located in the dermis), with a lower integrated flux in the upper tissue above the focal region. This focal geometry can help reduce excess heating or thermal damage in the upper tissue above the pigmented dermis region. The exemplary optical arrangement can also include a collimating lens arrangement configured to direct the EMR from the emitting arrangement to the focusing lens arrangement.
[0160] An exemplary phototherapy system can be configured to focus EMR to a focal region having a width or spot size of less than about 500 μm, such as less than about 100 μm or even less than about 50 μm (e.g., as small as about 1 μm). For example, the spot size can have a range from about 1 μm to about 50 μm, from about 50 μm to about 100 μm, and from about 100 μm to about 500 μm. The spot size of the focal region can be determined, for example, in air. This spot size can be selected as a balance between being small enough to provide a high flux or intensity of EMR in the focal region (to effectively irradiate pigmented structures in the dermis) and being large enough to facilitate irradiation of large areas / volumes of skin tissue within a reasonable treatment time.
[0161] High NA optical systems deliver different energy densities to different depths along the optical axis. For example, an optical system with a NA of about 0.5 will focus radiation to a focused focal region width (i.e., waist) of about 2 μm in diameter. The focal region has a power density of about 1 J / cm 2 Due to the high NA (i.e. fast) optical system, the radiation has 0.03 J / cm at a position only 10 μm out of focus. 2 The energy density of the radiation out of focus by only 30 μm is only 0.4% of the focused energy density (0.004 J / cm 2 ). This dramatic change in energy density along the optical axis enables depth-selective tissue treatment; but it also requires precise depth positioning (e.g., within tens of microns) of the focal region within the target tissue.
[0162] The exemplary optical arrangement can also be configured to direct the focal area of the EMR to a position within the dermal tissue at a depth below the skin surface, such as within a range of about 30 μm to about 2000 μm (e.g., between about 150 μm to about 500 μm). Such an exemplary depth range can correspond to a typical observation depth of a pigmented area in the skin that exhibits dermal dark spots or other targets of interest. The focal depth can correspond to the distance along the optical axis between the lower surface of the device configured to contact the skin surface and the position of the focal area. In addition, some embodiments can be configured to treat targets within the epidermis. For example, the optical arrangement can be configured to direct the focal area of the EMR to a position within the epidermal tissue (e.g., about 5 μm to about 2000 μm below the skin surface). Still other embodiments can be configured to treat targets deep in the dermis. For example, tattoo artists typically calibrate their tattoo guns to pierce the skin at a depth of about 1 mm to about 2 mm from below the skin surface. Thus, in some embodiments, the optical arrangement can be configured to direct the focal region of EMR to a location within the dermal tissue within a range from approximately 0.4 mm to 2 mm below the skin surface.
[0163] It may be desirable for a therapeutic system for tissue treatment to be able to identify a treatment area in a target tissue. (e.g., by imaging: pigments, interfaces between dermis and epidermis in the target tissue, cell membranes, etc.). It may also be desirable to monitor / detect interactions between EMR and the target tissue (e.g., plasma generation in the tissue). Additionally, based on the detection, the therapeutic system may modify the course of treatment (e.g., by changing intensity, size / location of the focal area in the target tissue, etc.). Various embodiments of the therapeutic system are described below.
[0164] For further overview, a table including parameter ranges for some exemplary embodiments is presented below.
[0165]
[0166]
[0167] where the depth of the focal region is the depth within the tissue (eg, the depth of the focal region = 0 may be at about the surface of the tissue), and M 2 is a parameter that characterizes the quality of the EMR beam.
[0168] Feedback detection and EMR-based treatment
[0169] Figure 5 5 is a schematic illustration of a treatment system 500. The treatment system 500 may include an optical system 502, an EMR detection system 504, and a controller 506. The optical system 502 may include an optical element (e.g., one or more of a mirror, a beam splitter, an objective lens, etc.) for guiding the EMR 510 generated by a source (e.g., a laser) to a focal area 552 of a target tissue 550. The EMR 510 may include imaging radiation for imaging the dermis and / or epidermis of the target tissue 550 (e.g., skin). The EMR 510 may also include therapeutic radiation for treating an area in the target tissue (e.g., area 522 of the target tissue 550). In some embodiments, the EMR 510 may include only one of the imaging radiation and the therapeutic radiation in a given time period. For example, the EMR 510 may include therapeutic radiation for a first duration and imaging radiation for a second duration. In other embodiments, the EMR 510 may include both imaging radiation and therapeutic radiation in a given time period. According to some embodiments, the imaging radiation has a wavelength that is generally equal to the wavelength of the therapeutic radiation; and the imaging radiation has a power less than the therapeutic radiation. According to another embodiment, the imaging radiation is provided by an imaging radiation source other than the source providing the therapeutic radiation, and the imaging radiation has a different wavelength than the therapeutic radiation.
[0170] The EMR detection system 504 (e.g., a photodiode, a charge coupled device (CCD), a spectrometer, a photomultiplier tube, etc.) can detect signal radiation 512 generated by the target tissue 550 due to its interaction with the EMR 510 and / or a portion of the EMR 510 reflected by the target tissue. For example, EMR 510 (e.g., therapeutic radiation) having an intensity above a threshold can generate plasma in the target tissue. The plasma can generate the signal radiation 512, for example, due to the interaction of the plasma with the EMR 510. The signal radiation 512 can represent a characteristic of the plasma (e.g., the presence of the plasma, the temperature of the plasma, the size of the plasma, the components of the plasma, etc.).
[0171] In some embodiments, EMR 510 (e.g., imaging radiation) having an intensity below a threshold can interact with the target tissue 550 without significantly perturbing the target tissue 550 (e.g., without damaging the target tissue 550, without generating plasma in the target tissue 550, etc.). Signal radiation 512 generated from this interaction can be used to image the target tissue 550 (e.g., the portion of the target tissue 550 in the focal region of the EMR 510). The signal radiation 512 can be used to detect pigments in the target tissue 550 (e.g., pigments located in the focal region of the target tissue). According to some embodiments, non-pigmented tissue is imaged. For example, when the imaging radiation (e.g., EMR 510) passes through a cellular structure with a different refractive index, the light is reflected as signal radiation 512.
[0172] The optical system 502 and the EMR detection system 504 can be communicatively coupled to a controller 506. The controller 506 can change operating parameters of the treatment system 500 (e.g., by controlling the operation of the optical system 502). For example, the controller 506 can move a focal region 552 of the EMR 510 in the target tissue 550. As discussed in more detail below, this can be accomplished, for example, by moving the optical system 502 relative to the target tissue 550 and / or by moving an optical element within the optical system 502 (e.g., by controlling an actuator coupled to the optical element) to change the position of the focal region 552. The controller 506 can receive data characterizing the optical detection of the signal radiation 512 from the EMR detection system 504.
[0173] The controller 506 can control the characteristics of the EMR 510. For example, the controller 506 can instruct a source of the EMR 510 (e.g., a laser source) to change the characteristics of the EMR 510 (e.g., intensity, repetition rate, energy per pulse, average power, etc.). In some embodiments, the controller 506 can change the optical characteristics of the EMR 510 (e.g., the location of the focal region, beam size, etc.) by placing / controlling an optical element (e.g., an objective lens, a diffractive optical element, etc.) in the path of the EMR. For example, the controller 506 can place an objective lens in the path of the EMR 510 and / or move the objective lens along the path of the EMR 510 to change the size of the focal region of the EMR 510.
[0174] The controller 506 can determine various characteristics of the target tissue 550 and / or the interaction between the EMR 510 and the target tissue 550 (e.g., plasma generation in the target tissue 550) based on the detection of the signal radiation 512 from the EMR detection system 504. In one embodiment of the treatment system 500, the controller 506 can determine one or more of the distribution of pigment in the target tissue 550, the topography of the dermis-epidermis junction, etc. In addition, the controller 506 can be configured to generate a map of the detected distribution indicating one or more of the aforementioned characteristics of the target tissue 550. Such determination of distribution and / or generation of distribution maps may be referred to herein as imaging.
[0175] In some embodiments, the target tissue 550. For example, in a Cartesian coordinate system, the target can be scanned along one or more axes (e.g., along an x-axis, a y-axis, a z-axis, or a combination thereof). In alternative embodiments, the scan can be performed according to other coordinate systems (e.g., cylindrical coordinates, spherical coordinates, etc.). The scan can be performed using an imaging beam (e.g., an EMR 510 having an intensity below a threshold), and the signal radiation 512 corresponding to various regions in the target tissue 550 in the path of the imaging beam can be detected by the EMR detection system 504. The characteristics (e.g., intensity) of the signal radiation 512 can be changed based on the pigment in the portion of the target tissue 550 that interacts with the imaging beam (e.g., the pigment in the focal area 552 of the imaging beam). The controller 506 can receive a signal from the EMR detection system 504, which can include data characterizing the detected characteristics (e.g., intensity) of the signal radiation 512. The controller 506 can analyze the received data (e.g., compare the received data with a predetermined characteristic value of the detected signal radiation 512 in a database) to determine the presence / characteristics of the pigment in the target tissue 550.
[0176] In some embodiments, the controller 506 can determine the location of a portion of the target tissue 550 to be treated (the "target treatment area") based on the signal radiation 512. For example, it may be desirable to treat a layer in the target tissue 550 that is located at a predetermined depth from the surface of the target tissue 550 (e.g., the dermis layer in skin tissue). The optical system 502 can be adjusted (e.g., by positioning the optical system 502 a desired distance from the surface of the target tissue 550) so that the focal area 552 is incident on the surface of the target tissue 550. This can be accomplished, for example, by scanning the optical system 502 along the z-direction until the signal radiation 512 exhibits predetermined characteristics indicative of an interaction between the EMR 510 and the surface of the target tissue 550. For example, an interface material (e.g., an optical plate, a gel, etc.) can be placed on the surface of the target tissue 550, and as the focal area 552 transitions from the target tissue 550 to the interface material, the characteristics of the signal radiation 512 can change. This can indicate the location of the focal area 552 of the EMR 510 at or near the surface of the tissue. Once optical system 502 is positioned so that focal region 552 of EMR 510 is at or near the surface of target tissue 550 , optical system 502 may be translated (eg, along the z-direction) so that focal region 552 is at a predetermined depth below the surface of target tissue 550 .
[0177] The controller 506 may change operating parameters of the treatment system 500 based on a signal received from the EMR detection system 504, the signal including data characterizing detected characteristics of the signal radiation 512. For example, some embodiments of the EMR detection system 504 may detect the depth of the dermis-epidermis (DE) junction in the target tissue 550, and the controller 506 may adjust the depth of the focal region 552 in response to the depth of the DE junction. In this manner, the DE junction may be used as a reference for determining the depth of the focal region 552 within the dermis. In addition, some embodiments of the EMR detection system 540 may quantify the proportion of melanin present in the epidermis layer of the skin (e.g., via the use of a spectrophotometer). Based on the proportion of melanin, the controller 506 may suggest one or more changes in laser parameters to a designated person (e.g., a clinician). According to some embodiments, the changes in the laser parameters may include at least one of: changing the energy per pulse inversely proportional to the detected proportion of melanin; increasing the focus angle as the proportion of melanin increases; and modifying the depth of the focal region 552 based on the proportion of melanin.
[0178] In some embodiments, an acoustic sensor 530 (e.g., an acoustic sensor) can be coupled to the target tissue 550, and the acoustic sensor 530 can detect characteristics of the interaction between the EMR 510 and the target tissue 550. For example, the acoustic sensor can detect pressure waves 552 generated by the formation of plasma (e.g., plasma generated in the focal region 552) in the target tissue 550. Examples of the acoustic sensor 530 can include: piezoelectric transducers, capacitive transducers, ultrasonic transducers, Fabry-Perot interferometers, and piezoelectric films.
[0179] In one aspect, pressure wave 532 can be a shock wave, a sudden change in pressure that propagates through a medium (e.g., air) at a speed faster than the speed of sound in the medium. In another aspect, pressure wave 532 can be a sound wave, which propagates through the medium at a speed approximately equal to the speed of sound in the medium.
[0180] Photoacoustic imaging (optoacoustic imaging) is a biomedical imaging modality based on the photoacoustic effect. In photoacoustic imaging, non-ionizing laser pulses are delivered into biological tissue (when radio frequency pulses are used, the technique is called thermoacoustic imaging). Some of the delivered energy will be absorbed and converted to heat, resulting in transient thermoelastic expansion and, therefore, broadband (i.e., MHz) ultrasound emission.
[0181] Sensor measurement data from the acoustic sensor 530 may be transmitted to the controller 506. The controller 506 may use this data to verify pigment detection via the signal radiation 512. According to some embodiments, treatment is confirmed by detecting the shock wave 532. The presence and / or intensity of the pressure wave 532 is correlated to the plasma generated and the plasma-mediated treatment performed. Additionally, by mapping at which focal regions the pressure wave 532 is detected, a comprehensive map of the treated tissue may be created and documented.
[0182] Figure 6 is a diagram illustrating an illustrative embodiment of an optical system 600. The optical system 600 can direct an EMR beam 602 from an EMR source 605 to a target tissue 650. The EMR source 605 can be a laser (e.g., a Q-smart450 laser from Quantel, which has a pulse energy of 450 mJ, a pulse duration of 6 nanoseconds [nS], and a wavelength of 1064 nm or a harmonic of 1064 nm). According to some embodiments, the EMR beam 602 can be introduced into the optical system 600 via an adapter 610. The adapter can be configured to secure the EMR source generating the EMR beam 602 to an articulated arm, for example Figure 1 The arm 20 of the mounting platform 12 .
[0183] According to some embodiments, a diffractive optical element (DOE) 620 (e.g., a beam splitter, multi-focus optics, etc.) can be placed in the path of the EMR beam 602. The DOE 620 can change the characteristics of the EMR beam 602 and transmit a second EMR beam 604. For example, the DOE 620 can generate multiple sub-beams focused to different focal areas. Implementations and uses of DOEs for treating target tissues are discussed in more detail in U.S. Provisional Application No. 62 / 656,639, entitled "Diffractive Optics for EMR-Based Tissue Therapy," the entire contents of which are incorporated herein by reference. The second EMR beam 604 (e.g., multiple sub-beams generated by the DOE 620) transmitted by the DOE 620 can be directed toward the target tissue 650 by a beam splitter 640 (e.g., a dichroic beam splitter). An example of a dichroic beam splitter can include a short pass dichroic mirror / beam splitter (Thorlabs PNDMSP950R) having a cutoff wavelength of about 950 nm, a transmission band between about 420 nm and about 900 nm, and a reflection band between about 990 nm and about 1600 nm. The second EMR beam 604 can be reflected by the beam splitter 640 and directed to the objective 660. The objective 660 can focus the EMR beam 604 to a focal region 652 in the target tissue 650 via a window 645. An example of the objective 662 is an Edmunds Optics PN 67-259 aspheric lens having a diameter of about 25 millimeters (mm), a numerical aperture (NA) of about 0.83, a near infrared (NIR) coating, and an effective focal length of about 15 mm. The window 645 can be used to hold the target tissue 650 in place.
[0184] In some embodiments, the EMR beams 602, 604 can be expanded by a beam expander (not shown) placed in the path of the EMR beams 602, 604. Beam expansion can achieve a desired NA value for the optical system 600. For example, a laser beam generated by a Q-smart 450 laser can have a beam diameter of about 6.5 mm and may require a beam expander that can expand the laser beam to twice the diameter. The expanded EMR beams 602, 604 can be focused using an approximately 15 mm EFL lens to focus the EMR beams 602, 604 with a sufficiently high NA (e.g., greater than 0.3).
[0185] The optical system 600 can be arranged so that the focal region 652 of the EMR beam 604 is located below the epidermis of the target tissue 650. This can be accomplished, for example, by moving the optical system 600 relative to the target tissue 650 and / or moving the objective lens 660 along the beam path of the EMR 604. In one embodiment, the position of the optical system 600 / optical elements in the optical system 600 can be moved by a controller (e.g., controller 506). Placing the focal region 652 below the epidermis (e.g., below the dermis-epidermis (DE) junction) can reduce or substantially inhibit undesirable heat generation in the epidermis, which can result in hyperpigmentation or hypopigmentation of the epidermis. This can also allow for targeting of areas in the dermis to achieve heat and / or plasma generation.
[0186] The interaction between the second EMR beam 604 and the target tissue 650 can result in the generation of signal radiation 606. As described above, the signal radiation 606 can include radiation generated by the plasma in the target tissue 650 ("tissue radiation"). The tissue radiation can have a wavelength that is located in the transmission band of the beam splitter 640. Therefore, the tissue radiation can be mainly transmitted by the beam splitter 640. The signal radiation 606 can also include radiation having a wavelength similar to the wavelength of the second EMR beam 604 ("system radiation"). The wavelength of the system radiation can be located in the reflection band of the beam splitter 640. Therefore, a small portion (e.g., 10%) of the system radiation is transmitted by the beam splitter 640.
[0187] Signal radiation 608 transmitted by beam splitter 640 may include tissue radiation and system radiation (or a portion thereof). Portions of signal radiation 608 may be captured by EMR detector 690. EMR detector 690 may transmit data characterizing detection of signal radiation 608 (or a portion thereof) to a controller (e.g., controller 506). The controller may, for example, alter operation of source 605 (e.g., shut off source 605) based on the detection (e.g., the intensity of transmitted signal radiation 608).
[0188] In one embodiment, the optical system 600 can be used as a confocal microscope. This can be accomplished, for example, by placing a second objective lens (not shown) upstream of the aperture 680. The aperture can re-image the signal radiation 606 by focusing on a focal plane including the aperture 680. The aperture 680 can filter (e.g., block) undesirable spatial frequencies of the signal radiation 608. This configuration can allow filtering of signal radiation associated with different regions in the target tissue 650 (e.g., regions of the target tissue at different depths relative to the tissue surface 654). By changing the distance between the imaging aperture 680 and the target tissue 650 (e.g., by moving the imaging aperture 680 along the path of the signal radiation 608), different depths of the target tissue can be imaged. In some embodiments, a controller (e.g., the controller 506) can move the imaging aperture 680 by transmitting a command to an actuator. The controller 506 can analyze the detection data and determine the presence of plasma in the target tissue 650, the distribution of pigments in the target tissue, etc. The optical system 600 can be used to detect damage in the window 645. Damage to the window 645 may be caused by an interaction between the second EMR beam 604 and the window 645 (e.g., when the intensity of the EMR beam is high, a prolonged interaction with the EMR beam 604, etc.). Detection of damage in the window 645 may be performed by determining a change in the intensity of the signal radiation due to damage in the window 645. This may be done, for example, by positioning the focal region 652 to be incident on the window 645 (e.g., incident near the surface of the window 645, incident at the surface of the window 645, incident within the window 645) and detecting the intensity of the signal radiation 606 (e.g., by using a photodetector as the EMR detector 690). This intensity may be compared to an intensity previously measured when the focal region 652 was located at a comparable position of the undamaged window 645. Based on the comparison, damage in the window 645 may be determined.
[0189] Figure 7 6 is an illustration of an embodiment of an optical system 700. The optical system 700 can include a microscope attachment 770 having an eyepiece 790. The microscope attachment 770 can capture the signal radiation 608 (or a portion thereof) transmitted by the beam splitter 640. The signal radiation 608 can be re-imaged by a tube lens 750 (e.g., an Edmunds Optics PN 49-665 25 mm diameter x 50 mm EFL Aspheric Achromatic Lens). The tube lens 750 can re-image the signal radiation 608 to a pupil plane 720 of an eyepiece 790 (e.g., an Edmunds Optics PN 35-689 10X DIN eyepiece).
[0190] As described above, the signal radiation 608 may include both tissue radiation and system radiation. Due to the difference in the wavelengths of these radiations, images of tissue radiation and system radiation are generated at different locations (e.g., at different planes). Therefore, if the eyepiece 790 is positioned to capture an image generated by the system radiation, it may not accurately capture an image associated with the tissue radiation. However, the eyepiece 790 can be calibrated to capture signal radiation having a wavelength different from the system radiation at the focal region of the system radiation. One calibration method is to use a material having a refractive index similar to that of the target tissue 650 as a phantom (e.g., acrylic). The calibrating eyepiece 790 may include focusing the second EMR beam 604 into the phantom (e.g., through the objective lens 660) and causing a breakdown (e.g., laser-induced optical breakdown) at the focal region of the second EMR beam 604. The intensity of the EMR radiation having a predetermined wavelength can then be measured by irradiating the second EMR radiation having a predetermined wavelength onto the phantom (e.g., at an oblique angle) and measuring the intensity of the EMR radiation having a predetermined wavelength at the eyepiece 790. The axial position of the eyepiece 790 can be adjusted (e.g., along the z-axis) to maximize the intensity of the detected radiation from the second EMR source. In some embodiments, a sensor can be used instead of the eyepiece 790. Examples of sensors can include CMOS and CCD images. The sensor generates a digital image in response to the radiation at the sensor plane. The digital image represents an image of the focal area 652.
[0191] Figure 8 800. The optical system 800 of FIG. 800 is an illustration of an embodiment of an optical system 800 having a fiber coupler attachment 802. The fiber coupler attachment 802 includes a lens barrel 810 that can image light from the objective lens 660 and the beam splitter 640 as described above. The lens barrel 810 can focus the signal radiation 608 at a pupil plane 815 (e.g., a plane parallel to the xy axis and including a collimating lens 820). The focused signal radiation 608 can be collimated to a desired size using the collimating lens 820 and can be directed to a coupling lens 830. The coupling lens 830 can focus the signal radiation 608 using a NA that is desirable for coupling to an optical fiber attached to a fiber connector 840. The optical fiber can be optically connected to one or more EMR detectors (e.g., detector 504). According to some embodiments, the coupler attachment 802 can also include an imaging aperture 850 located at the pupil plane 815. The aperture can filter portions of the signal radiation 608 that are not emitted from the focal region 652. According to some embodiments, detection instruments (e.g., photodiodes, spectrometers, etc.) can be placed directly after the imaging aperture 850 without optical fibers or associated optics. Calibration of the imaging aperture 850 relative to the lens barrel 810 can be accomplished in a process similar to that described above with reference to the calibration of the eyepiece 790.
[0192] Feedback detection can be used in conjunction with EMR-based therapy in many ways. Exemplary applications are described below to demonstrate some of the ways in which feedback-informed EMR therapy can be practiced. Broadly speaking, the examples described below can be categorized into three types of feedback-informed EMR therapy. These three categories encompass examples of: 1) detecting plasma; 2) referencing focal region locations; and 3) imaging tissue. These three categories of use are not intended to be an exhaustive (or mutually exclusive) list of applications for feedback-informed EMR-based therapy.
[0193] Plasma Feedback Example
[0194] Some treatments include forming a plasma (e.g., a thermal ionic plasma or optical breakdown) during treatment. In some embodiments, the characteristics of the detected plasma indicate the potential effectiveness of the treatment. For example, when treating a dermal pigment condition, the focal area is located deep in the skin so that the focal area will coincide with the dermal pigment when scanned during treatment. As the focal area is scanned over the skin, the laser source delivers pulsed laser light so that a thermal ionic plasma is formed at a location where the focal area coincides with the dermal pigment. The formation of a thermal ionic plasma indicates 1.) the presence of pigment in the skin; 2.) the pigment at the time of plasma formation is juxtaposed with the focal area (e.g., XY coordinates and depth); and 3.) the pigment at that location has been treated (e.g., the pigment has been destroyed).
[0195] In other cases, plasma formation can indicate the need for system maintenance. For example, some systems include a window placed in contact with the tissue being treated. The window can provide many functions, including: contact cooling; stabilizing the tissue; providing a depth reference for the tissue; and extracting blood or other fluids from the tissue by pressure. Radiation (such as a laser beam) also passes through the window for treatment of the treatment area below it. In some cases, the radiation can cause a breakdown within the window or at the surface of the window, resulting in plasma generation and window etching. If the system continues to deliver radiation after plasma generation at the window, it will generally result in burns or thermal damage to the tissue in direct contact with the window.
[0196] Fig. 9 A flow chart of a plasma detection method 900 during radiation-based tissue treatment according to some embodiments is illustrated. First, a surface of tissue is contacted with a window (906). The window contacts the outer surface of the tissue. The window is configured to transmit the therapeutic radiation. Typically, the window provides a reference surface such that the surface of the tissue is effectively referenced to the outer surface of the tissue when placed in contact with the window. According to some embodiments, the window provides additional functions, including, but not limited to, preventing movement of the tissue during treatment; contact cooling of the treated tissue; and drawing out blood (or other competing chromophores) within the tissue by compression.
[0197] Therapeutic radiation is then generated (908). Therapeutic radiation is typically generated by a radiation source. Therapeutic radiation is configured to produce an effect in the tissue, which can result in an improvement in appearance or a desired change. In some embodiments, the tissue effect can be cosmetic. In some other embodiments, the tissue effect can be therapeutic. According to some embodiments, the tissue effect includes generating a selective hot ionic plasma in the presence of a chromophore. The selection of parameters for the therapeutic radiation depends on the treatment being performed as well as the tissue type and the individual patient. Details related to the generation of therapeutic radiation 900 and the selection of related parameters for producing an effect (e.g., a cosmetic effect) in the tissue are described in detail above.
[0198] The therapeutic radiation is focused to a focal region (910). Typically, the therapeutic radiation (910) is focused by focusing optics. According to some embodiments, the focal region has a width of less than about 1 mm, about 0.1 mm, about 0.01 mm, or about 0.001 mm. The focal region can be positioned at a first region. In some embodiments, the first region is located within the tissue, specifically at the location to be treated. In some cases, the first region can be intentionally or unintentionally located outside the tissue, such as within a window in contact with the tissue.
[0199] The focal region is scanned (912), typically by a scanning system (e.g., a scanner). Examples of scanning include: tipping / tilting the focal region; rotating the focal region; and translating the focal region. Further description of related scanning means is described in U.S. Patent Application No. 16 / 219,809 to Dresser et al., "Electromagnetic Radiation Beam Scanning Systems and Methods," which is incorporated herein by reference in its entirety. According to some embodiments, the therapeutic radiation is pulsed so that while the focal region is scanned (e.g., moving from a first region to a second region), little or no therapeutic radiation is delivered. The focal region can be scanned continuously. In such a case, the timing and scanning parameters of the therapeutic radiation pulses control the positions of the first region and the second region.
[0200] Plasma is generated by the therapeutic radiation (914). Plasma is typically generated in or near the focal region because the flux is at a maximum in the focal region. According to some embodiments, plasma is selectively generated by thermionic plasma generation to pigment the region (914). Alternatively, plasma can be generated by non-selective laser-induced optical breakdown (914).
[0201] The plasma is then detected (916). The detector typically detects (916) signal radiation emitted from the plasma. Examples of signal radiation detection include: optical detection, acoustic detection, spectral detection of laser induced breakdown (e.g., laser induced breakdown spectroscopy), plasma generated shock wave (PGSW) detection, plasma luminescence detection, plasma (plume) shielding detection, and plasma photography. In some embodiments, characteristics of the plasma are determined based on the detection (916) of the plasma. Examples of characteristics of the plasma include: presence of the plasma, intensity of the plasma, spectral content of the plasma, and location of the plasma. According to some embodiments, the characteristics of the signal radiation are recorded and stored, for example, by a controller.
[0202] In some embodiments, a determination is made based on the detected plasma whether the plasma is at least partially within the window (918). For example, in some embodiments, optical signal radiation including spectral components known to represent material in the window but not in the tissue may be detected, indicating that the plasma is partially within the window. In another version, the intensity of the optical signal radiation may exceed a known threshold, meaning that the plasma is at least partially within the window.
[0203] Based in part on the detected plasma, such as the determination (918) of whether the plasma is partially within the window, parameters associated with the therapeutic radiation are controlled (920). Examples of parameters associated with the therapeutic radiation may include, but are not limited to, energy per pulse, repetition rate, location of the focal region, or size of the focal region. These therapeutic radiation parameters may be employed alone or in combination with one another or with other therapeutic radiation parameters without limitation. For example, a determination that the plasma is partially within the window may be used as a triggering event to end the therapeutic radiation.
[0204] In some embodiments, a map is generated that may include a matrix of properties mapped, for example, by a controller to positions. As an example, a map may include: a first property of a first signal radiation emitted from a first plasma at a first position may be mapped to coordinates for the first position, and a second property of a second signal radiation emitted from a second plasma at a second position may be mapped to coordinates for the second position. An exemplary map may include a four-dimensional matrix having three orthogonal axes associated with the position of the focal region and a fourth axis associated with one or more properties of the plasma. In some versions, the map may be used as an indication of the effectiveness of treatment for an individual. A system suitable for performing the plasma detection method described above is described in detail below.
[0205] See also Fig.10, shows a schematic diagram of a plasma detection and treatment system 1000 according to some embodiments. In some embodiments, a window 1006 is configured to contact a surface of a tissue 1008, such as an outer surface of the tissue 1008. The window 1006 includes an optical material configured to transmit an EMR beam, such as glass, a transparent polymer (e.g., polycarbonate), quartz, sapphire, diamond, zinc selenide, or zinc sulfide.
[0206] The imaging and treatment system 1000 includes a focusing optic 1010. The focusing optic 1010 (e.g., an objective lens) is configured to focus an electromagnetic radiation (EMR) beam 1011 and generate a plasma 1012 within the tissue 1008. The plasma may be selectively generated at chromophores within the tissue 1008 by thermal ionization. In some other embodiments, the plasma 1012 is non-selectively generated by optical breakdown. A radiation source (not shown) may be used to generate the EMR beam 1011. The EMR beam 1011 may include any of collimated or non-collimated light and coherent and incoherent light.
[0207] Detector 1014 is configured to detect plasma 1012. Examples of plasma detectors 1014 include: photoelectric sensors, such as photodiodes and image sensors; acoustic sensors, such as surface acoustic wave sensors, piezoelectric films, vibrometers, and etalons; and more specialized detectors, such as spectrometers, spectrophotometers, and plasma brightness (or shielding) optical probes.
[0208] In the illustrated embodiment, the plasma detector includes a photodetector (e.g., a photodiode) that senses visible light 1016 (e.g., signal radiation) emitted from the plasma 1012. According to some embodiments, a tube lens 1018 is used in conjunction with the focusing optics 1010 to direct and focus the visible light 1016 incident on the detector 1014. The detector 1014 is in communication with the controller 1015 so that data associated with the detected plasma is input to the controller 1015.
[0209] The scanner 1022 is configured to scan the focal region of the EMR beam 1011. The scanner typically scans the focal region in at least one dimension. Moreover, in some embodiments, the scanner 1022 scans the focal region in all three dimensions. Fig.10 , the scanner 1022 is shown scanning the focus area from left to right from a first area 1024 to a second area 1026 of the tissue 1008.
[0210] As the scanner 1022 scans the focal region, the EMR beam 1011 can be pulsed to generate a first plasma at a first region 1024 and then a second plasma at a second region 1026. The first plasma and the second plasma are both detected by the detector 1014. In some embodiments, data associated with the first detected plasma and the second detected plasma are input to the controller 1015. In some embodiments, the data associated with one or more plasma events is used by the controller to control parameters associated with at least one of the EMR beam 1011 and the scanner 1022.
[0211] According to some embodiments, the controller 1015 is configured to control the EMR beam 1011 (e.g., terminate the EMR beam 1011) based on determining whether the plasma 1012 is at least partially located within the window 1008. In some versions, the controller 1015 determines whether the plasma 1012 is at least partially located within the window 1006 based on the intensity of the signal radiation 1016 emitted from the plasma 1012. A photoelectric sensor (e.g., a photodiode) can be used to detect the intensity of the signal radiation 1016. According to another version, the controller 1015 determines whether the plasma 1012 is at least partially located within the window 1006 based on the spectral components of the signal radiation 1016. For example, according to some embodiments, the window 1006 may include sapphire, which includes aluminum. The spectral peak corresponding to aluminum is centered at about 396 nm. Skin generally does not contain aluminum. Therefore, if the signal radiation (taken at a precise time [e.g., 10 μs] after the laser pulse is spent) includes a spectral peak centered at about 396 nm, then it is likely that the plasma 1012 is at least partially located within the window 1006. According to some embodiments, a spectral filter (eg, a notch filter) and a photoelectric sensor are used to detect the spectral content of the signal radiation. According to other embodiments, a spectrometer or a spectrophotometer is used to detect the spectral content of the signal radiation.
[0212] The controller 1015 can be configured to record one or more detected characteristics of the plasma 1012. In some embodiments, the controller 1015 is configured to record a matrix (or map) of detected characteristics of the plasma 1012. For example, the controller 1015 can be configured to: record a first characteristic of a first signal radiated from the first plasma 1012 at a first location 1024; map the first characteristic to coordinates for the first location 1024; record a second characteristic of a second signal radiated from the second plasma at a second location 1026; and map the second characteristic to coordinates for the second location 1026.
[0213] A separate example is provided below to further explain plasma detection in an EMR therapy device.
[0214] Plasma Feedback Example 1
[0215] The first plasma feedback example describes an in vitro study that quantifies changes in relative plasma light intensity that demonstrate the presence of plasma. The in vitro study was performed with skin from female Yucatan pigs, which were selected for their dark skin. In the in vitro study, a 10W Nufern fiber laser with a wavelength of approximately 1060nm was used as the laser source.
[0216] Fig.11A is a schematic illustration of a treatment optical system 1100 used in an in vitro study. The treatment optical system 1100 includes a beam combiner 1110 configured to receive a collimated laser beam 1112. The beam combiner 1110 includes a reflector 1114 that reflects the incident laser beam 1112. The reflector 1114 is selected to reflect light having a predetermined wavelength range. In the current in vitro study, the laser beam 1112 has a wavelength of 1060nm, and the reflector is a Thorlabs NB1-K14, which has a reflectivity of 99.5% over a wavelength range of 1047nm to 1064nm. The reflected laser beam 1112 is imaged and focused by a focusing optic 1116. The focusing optic 1116 used in the in vitro study is a Thorlabs C240TME-C, which is an aspheric lens capable of diffraction-limited performance with an NA of 0.5 and an effective focal length of 8mm. The laser beam 1112 is focused to a waist (e.g., focal volume) in the skin sample 1118. At the waist of the laser beam 1112, a plasma plume 1120 is generated within the skin sample 1118. Radiation 1124 generated from the plasma plume 1120 is imaged by focusing optics 1116 and transmitted through reflector 1114. Radiation 1124 is imaged into a first end of an optical fiber (not shown) by a fiber coupler 1122 after being transmitted through reflector 1114. The fiber coupler used in the in vitro study is a Thorlabs PAF-SMA-7-A. The second end of the optical fiber is coupled to a spectrometer (not shown), which is an Ocean Optics HR2000+ES. In another embodiment of the in vitro study, a notch filter (not shown) is disposed between the reflector 1114 and the fiber coupler 1122 to prevent a portion of the radiation 1124 having a wavelength similar to that of the laser beam 1112 from entering the optical fiber. The skin sample 1118 is mounted on a motorized stage 1130. A working distance between the skin sample 1118 and the focusing optics 1116 is maintained to control the depth of the waist of the laser beam 1112 within the skin sample 1118 .
[0217] In another embodiment of the in vitro study, a skin sample 1118 with a melanin tattoo is placed on a motorized stage 1130 so that the waist of the laser beam 1112 is located at a depth of about 0.2 mm in the sample 1118. The melanin pigment used in the melanin tattoo is derived from cuttlefish ink (e.g., squid ink). The melanin tattoo is approximately between a quarter millimeter and one millimeter in the dermis of the skin sample. The depth of the tattoo pigment within the skin is verified by viewing a tissue sample of the skin.
[0218] Fig. 11B A scan of a tissue sample of a skin sample 1118 with a melanin tattoo is illustrated. The skin surface 1150 is shown on top of the tissue. The epidermis-dermis junction 1152 demarcates the boundary between the epidermis and dermis layers of the skin. Melanin droplets 1154 present in the dermis constitute the melanin tattoo. The laser was operated at 20KHz, a pulse duration of 100ns, and 0.5mJ / pulse. The sample was scanned at a rate of 100mm / s during laser irradiation. The spectrometer was adjusted to capture light within a period of 5000ms and the capture was triggered in response to laser irradiation.
[0219] Fig.12 The spectrum associated with radiation from clear skin with a melanin tattoo is illustrated. The horizontal axis represents the wavelength of radiation from the sample skin 1118, and the vertical axis represents the relative intensity of the radiation. Fig.12 A melanin tattoo spectrum (e.g., centered at about 600 nm) and a clear skin spectrum generated when skin 1118 is irradiated with a laser beam 1112 (e.g., having a spectrum centered at about 1060 nm) are illustrated. The melanin tattoo spectrum shows measurements taken during irradiation of a sample at the location of a melanin tattoo (e.g., when the waist / focal volume of the input laser beam 1112 irradiates a portion of the skin having a melanin tattoo). The clear skin spectrum shows measurements taken during irradiation of an area of the sample skin 1118 that does not include a melanin tattoo. The melanin tattoo spectrum shows the presence of broad spectrum light that includes radiation in the visible spectrum (e.g., between 400 nm and 800 nm). The broad spectrum light indicates plasma formation during irradiation of the melanin tattoo. The clear skin spectrum generally has no visible spectrum component or has a very small visible spectrum component. The lack of a visible light component in the clear skin spectrum indicates that plasma is generally not formed during irradiation of the clear skin.
[0220] Another skin sample 1118 with a carbon tattoo (e.g., India ink) was placed on a motorized stage 1130 below the focusing optics 1116 so that the focus waist of the laser beam was located approximately 0.2 mm below the surface of the skin sample 1118. The carbon tattoo was approximately between a quarter millimeter and a millimeter deep in the dermis of the skin sample 1118. The laser was operated at 20 KHz, a pulse duration of 100 ns, and 0.5 mJ / pulse. The sample was scanned at a rate of 100 mm / s during laser irradiation. The spectrometer was adjusted to capture light within a period of 5000 ms and the capture was triggered in response to laser irradiation.
[0221] Fig.13 The spectra associated with radiation from a carbon tattoo and clear skin are illustrated. The horizontal axis represents the wavelength of radiation from the sample skin 1118, and the vertical axis represents the relative intensity of the radiation. Fig.13 A carbon tattoo spectrum and a clear skin spectrum generated when skin 1118 is irradiated with a laser beam 1112 are illustrated. The carbon tattoo spectrum shows measurements taken during irradiation of a sample at the location of a carbon tattoo (e.g., when the waist / focal volume of the input laser beam 1112 irradiates the portion of the skin having the carbon tattoo). The clear skin spectrum shows measurements taken during irradiation of an area of the sample skin 1118 that does not include the carbon tattoo. The carbon tattoo spectrum shows the presence of broad spectrum light that includes radiation in the visible spectrum (e.g., between 400 nm and 800 nm). The broad spectrum light indicates plasma formation during irradiation of the carbon tattoo. The clear skin spectrum generally does not have a visible spectrum component. The lack of light indicates that plasma is generally not formed during irradiation of the clear skin.
[0222] It should be noted that the broad spectrum captured in the above experiment is produced by generating plasma at a rate of 20KHz at many locations, which is the repetition rate of laser beam 1112. The integration time of the spectrometer is set to 1ms or greater. This allows the spectral information of the plasma generated by multiple pulses of laser beam 1112 to be characterized. After the interaction between the incident laser pulse (of laser beam 1112) and the plasma, the plasma begins to cool and the energy level of its electrons decreases, thereby emitting light through narrow spectral bands. Since the above spectrometer measurement is integrated over multiple pulses, it should be understood that these narrow bands cannot be observed in this example. A second example in which narrow spectral bands are detected is described below.
[0223] Plasma Feedback Example 2
[0224] In a second example, experiments observed a narrow spectral band of radiation 1124 generated by plasma in skin sample 1118 . Fig.11AThe optical system used for this detection is described in . The optical system includes an optical fiber that allows optical communication between the optical system and an Ocean Optics spectrometer model HR 2000+ES. The optical system is in optical communication with a Q-switched Nd:YAG laser (Quantel Q-Smart 450) with an articulated arm so that the laser beam from the Q-switched Nd:YAG laser is directed into the system.
[0225] The skin sample 1118 is generally placed parallel to the focal region of the laser beam. The focal region is first placed just below the surface of the skin sample 1118. Multiple laser pulses are directed toward the sample skin 1118, with spectrometer measurements being taken immediately after each laser pulse. Each laser pulse has sufficient peak power to produce optical breakdown, resulting in the generation of a plasma in the skin sample 1118. Radiation 1124 from the plasma is captured and communicated to the spectrometer as described with reference to FIG. 11 .
[0226] Fig.14 The spectrum of radiation 1124 generated by the plasma in the skin sample 1118 is shown. The spectrum results captured from the plasma after each laser pulse are averaged. The average spectrum is shown in Fig.14 1400. Graph 1400 has relative intensity in arbitrary units along the vertical axis and wavelength in nanometers along the horizontal axis. The average spectrum includes spectral peaks at about 589nm and 766nm. The average spectrum also includes secondary spectral peaks at about 422nm, about 455nm, about 493nm, about 521nm, about 553nm, about 614nm, and about 649nm.
[0227] During experiments, a sapphire window was placed between the skin sample 1118 and the focusing optics 1116 along the path of the laser beam 1112. The laser beam 1112 was directed through the sapphire window into a waist / focal area located approximately 0.5 mm below the surface of the skin. Fig.15 1500 is a graph illustrating the spectrum of radiation from a plasma formed using a sapphire window in contact with tissue. Graph 1500 has relative intensity in arbitrary units along the vertical axis and wavelength in nanometers along the horizontal axis. Fig.15As can be seen in the 3D images, there are major peaks at about 589 nm and about 766 nm. In addition, an even larger peak is located at about 396 nm. After measurements, it has been found that the sapphire window is damaged (e.g., etched) in a manner consistent with plasma formation therein. The 396 nm peak reappears in the presence of a sapphire window, which only occurs when a sapphire window is present; moreover, the sapphire window appears to be damaged by plasma formation. This observation indicates that this peak at about 396 nm can be used as an indicator of plasma formation within a sapphire window.
[0228] According to some embodiments, the material component of the plasma is determined by spectral analysis, and one or more parameters of the laser beam are adjusted based on the material component of the plasma. For example, according to some embodiments, the controller determines from the spectral data that materials other than the material being processed are being affected by the plasma, and adjusts the laser parameters or disables the laser source. Although the second example uses a spectrometer to detect the spectral content of the plasma, some embodiments determine the spectral content of the plasma by alternative methods. For example, in some versions, a narrowband filter that only passes light centered about 396 nm is placed above the photodiode so that the photodiode detects only light at 396 nm. The photodiode is triggered to collect a time (moment) after (e.g., 10 μS) after the EMR pulse. Moreover, the controller is configured to stop emitting the EMR source when the photodiode detects a relatively high value, because a relatively high value only occurs when the plasma affects the sapphire window.
[0229] Plasma Feedback Example 3
[0230] A third example demonstrates a plasma detection system incorporated into an EMR-based therapy handpiece to detect plasma.
[0231] FIG. 16A to FIG. 16C A diagram according to a third example of tissue treatment and plasma detection is illustrated. FIG. 16A to FIG. 16C A tissue treatment and plasma detection system 1600 is shown in FIG. Fig.16A A front view of system 1600 is shown. Fig. 16B Shown along Fig.16A A cross-sectional view of the system 1600 taken along section line BB in FIG. Fig. 16C Shows from Fig. 16B Detail view captured within the C detail circle.
[0232] Fiber laser 1610 is configured to output therapeutic radiation. An example of fiber laser 1610 is a Feibo 1060nm, 40W, 20kHz fiber laser from Feibo Laser Technology Co., Ltd. in Shanghai, China. The therapeutic radiation is directed to focusing optics 1620 by an optical system. An example focusing optic is Thorlabs part number: A240. Focusing optics 1620 is configured to focus therapeutic radiation to a focal area in tissue (not shown) through window 1622. The optical system is configured to allow focusing optics 1620 to be scanned in all three dimensions. This then allows the focal area of therapeutic radiation to be scanned in all three dimensions within the tissue. Scanning is accomplished by three separate stages, each responsible for a single axis. X stage 1625 scans the focusing optics in the X axis. Y stage 1626 mounted to X stage 1625 scans the focusing optics in the Y axis. Also, a Z stage 1627 mounted to the Y stage 1626 scans the focusing optics in the Z axis (e.g., generally along the optical axis of the focusing optics). An exemplary X stage is a Dover MMX50 from Dover Motion, Inc., Bucksboro, MA, USA, controlled by an Elmo DC whistle Gold controller from Elmo Motion Control, Ltd., Petah Tikva, Israel. An exemplary Y stage is a Q545.140 stage controlled by an E 873 controller from Physik Instrumente LP, Auburn, MA, USA. An exemplary Z stage is a New Scale 3M-FS from New Scale Technologies, Inc., Victor, NY, USA.
[0233] A printed circuit board (PCB) 1640 is attached to the Z stage 1627 and faces the window 1622. The PCB 1640 contains several electronic components and four photodiodes 1642. An example photodiode is an Osram CHIPLED part number SFH 2711 from OSRAM GmbH, Munich, Germany. Another example photodiode is a gallium nitride based sensor, GUVA-S12SD from Roithner Lasertechnik GmbH, Vienna, Austria. These two example photodiodes may be advantageous in some embodiments because they are more sensitive at detecting light in the ultraviolet (UV) and visible spectrum than in the near infrared (NIR). To this end, these example photodiodes will detect light from the plasma, but detect less reflected or scattered therapeutic radiation (e.g., 1060 nm laser). In some other embodiments, the photodiodes may be coated with an optical coating (e.g., an interference notch filter coating) to prevent detection of therapeutic wavelengths. In yet other embodiments, the photodiodes may be placed behind a spectral filter (e.g., an interference notch filter film) to prevent detection of therapeutic wavelengths.
[0234] The light from the plasma is converted into a small current by one or more of the photodiodes 1642. The current is converted into a voltage by a transimpedance amplifier. The voltage is then amplified by one or more amplifiers and sampled by a microcontroller. The microcontroller samples the voltage using at least one of an analog-to-digital converter (ADC) and a comparator.
[0235] In some versions, a comparator compares the voltage to a threshold and triggers a timer (e.g., 32678 Hz) when the voltage exceeds the threshold. When the voltage remains above the threshold for a defined duration (e.g., 3 ticks of a timer), the microcontroller detects plasma. In some embodiments, the threshold is set high so that plasma originating from treatment within the tissue will not exceed the threshold, but plasma originating from closer and brighter plasma within the optical window will exceed the threshold. In such a case, the plasma detector can be used to detect excess plasma (such as plasma in the surrounding tissue or optical window) that may cause damage to the patient or the system. Once plasma is detected, a signal can be sent to another controller (e.g., a laser controller) that can record the plasma detection or modify the treatment (e.g., stop the therapeutic radiation) based on the detection.
[0236] According to some embodiments, the ADC can be used to detect plasma within the tissue (e.g., plasma consistent with treatment). The ADC assigns a digital value representing the plasma intensity based on the voltage from one or more photodetectors. In some cases, the digital value is recorded along with the current position value of one or more of the X stage 1625, the Y stage 1626, and the Z stage 1627. In such a case, the record of the digital value relative to the focal area position can be formatted as a matrix (e.g., a map). The matrix can be used to indicate the effectiveness of treatment or the presence of chromophores within the tissue.
[0237] In some embodiments, the presence of plasma at a first depth (e.g., relatively shallow) may indicate damage to the system or an adverse event, while the presence of plasma at a second depth (e.g., relatively deep within the tissue) may indicate effective treatment. Thus, in some embodiments, it is important to ensure that the focal region of the EMR beam is at a location within the desired focal depth.
[0238] Depth of Focus Reference Example
[0239] As described in detail above, in some embodiments, the depth of the focal area within the tissue needs to be closely controlled (e.g., + / - 20 μm). For example, treatment of dermal pigment requires placement of the focal area at a depth that is approximately the depth of the dermal pigment within the tissue. If the focal area is too deep below the dermal pigment treatment, the treatment will be ineffective. If the focal area is too shallow, the melanocytes at the basal layer will be irradiated, potentially causing adverse events (e.g., hyperpigmentation or hypopigmentation).
[0240] See also Fig.17 , a flowchart 1700 of a depth of focus reference method 1700 according to some embodiments is shown. First, an electromagnetic radiation (EMR) beam is focused to a focal region (1710) along an optical axis. In many cases, the EMR beam is generated by an EMR source (e.g., a laser). An optical window is arranged to intersect the optical axis. In some versions, the surface of the window is substantially orthogonal to the optical axis. The EMR beam is irradiated on at least one surface of the optical window, and signal radiation is generated. In some embodiments, the signal radiation includes a reflected portion of the EMR beam reflected at the surface of the window. In some embodiments, the window is configured to contact the tissue. The surface of the window can be optically understood as an optical interface between a window material of the window and an adjacent material (e.g., air or tissue) adjacent to the surface of the window. In some cases, the refractive index difference between the window material and the adjacent material can cause reflection of the reflected portion of the EMR beam. According to some embodiments, the signal radiation is generated by scattering or transmitting a portion of the EMR beam at the window.
[0241] Detecting signal radiation (1712). According to some embodiments, the signal radiation is imaged by an imaging system. In some cases, an image of the signal radiation is formed at a sensor by the imaging system. Examples of sensors include photoelectric sensors and image sensors. In some versions, the detector detects and measures the image width. In general, the image width will be proportionally related to the beam width of the EMR beam at the surface of the incident window. The magnification of the imaging system typically determines the ratio of the image width to the width of the EMR beam at the incident window. According to some embodiments, the detector detects and measures the intensity of the signal radiation.
[0242] Based on the signal radiation, a reference focal position is determined (1714). For example, in some versions, the beam width of the EMR beam at the surface of the entrance window is measured, and the focal position of the focal region is translated along the optical axis while measuring the beam width. The reference position is found where the beam width is determined to be at a minimum. For another example, in some versions, the intensity of the signal radiation is detected while translating the focal position of the focal region along the optical axis. In such a case, the reference position is found where the radiation signal intensity is found to be at a maximum.
[0243] Once the reference focal position is determined, the focal region is translated to the treatment focal position (1716). Typically, the treatment focal position is a predetermined distance from the reference focal position along the optical axis. According to some embodiments, the focal region is translated by moving an optical element (e.g., an objective lens) along the optical axis. In some other embodiments, the focal region is translated by adjusting the divergence of the EMR beam (e.g., adjusting the optical power of the optical element). Ultimately, the window is placed in contact with the target tissue, resulting in the focal region being positioned within the target tissue. According to some embodiments, the target tissue is skin, and the focal region is positioned within the dermis tissue of the skin. The precise deep positioning of the focal region within the tissue allows for the treatment of previously incurable pigmentary conditions by thermal ion plasma or thermal destruction. For example, the EMR beam can perform selective thermal ion-plasma mediated treatment of dermal pigmentary conditions (e.g., dermal melasma) at a focal region located within the dermis without the risk of adverse irradiation of the epidermis.
[0244] See also Fig.18B In some embodiments, the second EMR beam 1816B is configured to converge to a second focal region 1818B located in the treatment location via focusing optics. In such a case, the first EMR beam 1816A may be configured only as a reference (e.g., by delivering the first focal region 1818A incident on the surface of the window 1810), and the second EMR beam 1816B may be configured to achieve a desired effect (e.g., a cosmetic effect) in the tissue. This may be advantageous in an embodiment where a very high flux (e.g., 10 12 W / cm2 ), and if the first EMR beam were to be used during the reference period, window 1810 would likely be damaged. According to some embodiments, second EMR beam 1816B has a wavelength approximately equal to that of first EMR beam 1816A. In other embodiments, second EMR beam 1816B has a wavelength different from that of first EMR beam 1816A. In such a case, the treatment position may require calibration based on the difference in focal length of the focusing optics at the two different wavelengths.
[0245] View now FIG. 18A to FIG. 18B , shows a schematic diagram of a depth of focus reference and treatment system 1800 according to some embodiments. The depth of focus reference system 1800 includes a window 1810 configured to contact a target tissue 1812. An optical system (e.g., an objective lens or focusing optics) is configured to focus an electromagnetic radiation (EMR) beam 1816 to a focal region 1818 along an optical axis 1820. The optical axis 1820 intersects the window 1810. An optical detector 1822 is configured to detect signal radiation 1824. According to some embodiments, the signal radiation 1824 is generated by an interaction between the EMR beam 1820 and the window 1810. In some versions, the interaction between the EMR beam 1820 and the window 1810 is an interaction between a surface of the window 1810 and the EMR beam. The interaction between the EMR beam 1820 and the window 1810 is typically at least one of reflection, transmission, and scattering.
[0246] Controller 1826 is configured to take input from optical detector 1822 and translate the focus position of focus region 1818 along optical axis 1820. Based at least in part on feedback from optical detector 1822, controller 1826 determines a reference position 1828 where a portion of focus region 1818 substantially coincides with a surface of window 1810.
[0247] Signal radiation 1824 may be emitted from a reflection of the EMR beam 1816 incident on the surface of the window 1810 and imaged by impinging on the image sensor 1822 using (partial) focusing optics 1814. According to some embodiments, the controller 1826 determines a reference position by determining a lateral width of the EMR beam 1816 incident on the surface of the window based on the signal radiation; and, translating the focus region until the lateral width has a minimum value. According to another embodiment, the signal radiation is emitted from a reflection of the EMR beam 1816 at the surface of the window 1810, and the detector 1822 is configured to detect the intensity of the signal radiation. In such a case, the controller may determine the reference position by translating the focus region until the intensity of the signal radiation has a maximum value.
[0248] Finally, the controller 1826 translates the focal region 1818 to a treatment position that is a predetermined distance 1830 from the reference position 1828. Generally speaking, translating the focal region 1818 away from the reference position 1828 is performed in a positive direction (i.e., away from the optical system 1814) along the optical axis 1820. In some embodiments, the treatment position is configured to be located within the tissue. For example, the predetermined distance can be configured to locate the treatment position within the dermal tissue in the skin. The stage 1832 can be used to translate one or more optical elements (e.g., focusing optics) in order to translate the focal region. The EMR beam 1816 is typically configured to perform an effect (e.g., a cosmetic effect) in tissue at or near the focal region located in the treatment position. An example tissue effect is selective thermionic plasma-mediated treatment of tissue 1812.
[0249] In some embodiments, the second EMR beam is configured to converge to a second focal region located in the treatment location via focusing optics. In such a case, the first EMR beam may be configured only as a reference, and the second EMR beam may be configured to perform a tissue effect. This may be advantageous in an embodiment where a very high flux (e.g., 10 12 W / cm 2 ), and the window 1810 will likely be damaged during the reference period. According to some embodiments, the second EMR beam has a wavelength equivalent to the first EMR beam. In other embodiments, the second EMR beam has a wavelength different from the wavelength of the first EMR beam. In such a case, it will be necessary to calibrate the treatment position based on the difference in the focal length of the focusing optics at the two different wavelengths. In some embodiments, the window reference and treatment system 1800 is used to measure more than one reference position 1828.
[0250] For example, according to some embodiments, window reference and treatment system 1800 also includes a scanning system. The scanning system is configured to move focal region 1818 and optical axis 1820 on at least one scanning axis. In some cases, the scanning axis can be substantially perpendicular to optical axis 1820.
[0251] The parallelism measurement between the window and the scan axis can be determined by measuring at multiple reference positions 1828 at multiple scan positions. For example, the reference system 1800 is first used to determine a first reference position at a first scan position. The scanning system then repositions the optical axis 1818 to a second scan position that is a certain distance away from the first scan position along the scan axis. The reference system 1800 then determines the second reference position. The difference between the first reference position and the second reference position divided by the distance along the scan axis indicates the slope of the non-parallelism between the window and the scan axis. A separate example is provided below to further explain the depth of focus reference in an EMR treatment device.
[0252] Depth of focus reference example 1
[0253] A first focal depth reference example is described below. The first focal depth reference example employs a feedback system such as a confocal microscope. This configuration is advantageous in some embodiments because it can be used to reference surfaces within the tissue as well as external tissue surfaces and window surfaces. For example, according to some embodiments, the focal region is referenced relative to the dermis-epidermis (DE) junction within the skin. This is achievable in some embodiments due to the refractive index difference between the epidermis (or melanin in the basal layer of the epidermis) and the dermis.
[0254] Fig.19 A workbench prototype 1900 for confocal imaging and plasma-mediated therapy is illustrated. A collimated laser beam 1901 enters the prototype 1900 through an entrance aperture 1902 and is projected onto a reflector 1904. The reflector 1904 folds the laser beam 1901 toward an objective 1906. The objective 1906 focuses the laser beam 1901 to a focal region 1907. The focused laser beam 1901 is directed toward a sample holder 1908. The sample holder 1908 includes a window 1910 and a sample optically located downstream of the window 1910. Fig.19 The sample shown in is skin including epidermis 1912 and dermis 1914 optically located downstream of epidermis 1912. A compliant material, such as foam 1916, is used to press the sample against window 1910 and the window against the platform of sample holder 1908. The sample holder is placed on top of XY stages 1918X and 1918Y. Prototype 1900 scans the sample relative to the laser beam. Z stage 1920 allows adjustment of the distance between objective lens 1906 and sample holder 1908. A screw micrometer allows closely controlled movement of Z stage 1920. Objective lens 1906 collimates returned light 1922 from focal region 1907. Radiation 1922 is at least partially transmitted through reflector 1904. According to some embodiments, radiation 1922 passes through filter 1923 (e.g., notch filter) so that only a portion of radiation 1922 having a certain wavelength range is accepted. The radiation 1922 is focused by a tube lens 1924 to an aperture 1926. The aperture 1926 is sized to accept only light originating from the focal point 1907 (eg, less than 50 μm). Finally, the radiation 1922 is projected onto a photodiode 1928.
[0255] In one embodiment, the optical system 1900 is used as a confocal microscope. This can be accomplished, for example, by placing the second objective lens 1924 upstream of the aperture 1926. The aperture 1926 can re-image the signal radiation 1922 by focusing the signal radiation at a focal plane including the aperture 1926. The aperture 1926 can filter (e.g., block) undesirable spatial frequencies of the signal radiation 1922. This configuration can allow filtering of signal radiation associated with different regions in the target tissues 1912 and 1914 (e.g., regions of the target tissue at different depths relative to the tissue surface). By changing the distance between the imaging aperture 1926 and the target tissues 1912 and 1914 (e.g., by moving the imaging aperture 1926 along the path of the signal radiation 1922), different depths of the target tissue can be imaged (1926) by transmitting commands to the actuator. The controller 506 can analyze the detection data and determine the presence of plasma in the target tissues 1912 and 1914, the distribution of pigments in the target tissues, etc.
[0256] Focusing the laser beam at a specified depth below the surface requires precise placement of the focal region 1907 relative to the surface. Therefore, in some embodiments, it is advantageous to determine the position of the objective lens 1916 relative to the surface of the sample (e.g., the surface of the sample facing the objective lens 1906). This can be done by referencing the focal region 1907 to the surface of the sample. Using a bench prototype as described above, tests were performed to determine where the focal region was located relative to the top and bottom surfaces of the window 1910 and relative to the top surface of the pigskin sample.
[0257] A Nufern 30W fiber laser operating at a wavelength of 1060nm is used to provide a laser beam 1901 having a diameter of about 7.5mm. Reflector 1904 is a dichroic mirror that reflects more than 90% of the laser beam 1901 at a wavelength of 1060nm and transmits less than 10%. The objective lens has an effective focal length of about 8mm. The lens barrel 1924 focuses the returned light 1922 with an effective focal length of about 30mm. The aperture 1926 is about 30 microns wide. The fiber laser is operated at a power level of 0.1% (1mJ / pulse) and a repetition rate of 30KHz. The signal from the photodiode 1928 is displayed on an oscilloscope. When the fiber laser is turned on, the Z stage 1920 is scanned slowly until the maximum signal is captured by the oscilloscope.
[0258] Fig. 20The maximum radiation intensity measurement is illustrated. Intensity is shown in arbitrary units along the vertical axis, and time is shown along the horizontal axis. The maximum radiation intensity signal 2002 is generated when the focal region 1907 is placed on the top surface of the window 1910. The Z stage 1920 micrometer reports a relative position of 0.487 mm where the maximum signal 2002 is observed. No detectable signal is observed at relative Z stage positions of 0.458 mm and 0.519 mm.
[0259] In the above example, the position of the focal region is referenced at the window interface, where the reflection at the interface is found to be maximum. The difference in refractive index between the materials causes reflection at the interface between the two materials (e.g., air and a window). Reflection caused by a mismatch in refractive index is sometimes understood to be a Fresnel reflection. Fresnel reflection changes with the angle of incidence and the polarization of the light. For simplicity, Fresnel reflection at a normal angle of incidence (which does not depend on polarization) will be shown as an example. Normal Fresnel reflection generated at the boundary between materials with different refractive indices will generally work according to the following equation:
[0260]
[0261] Where R is the reflectivity (the fraction of light that is reflected), n1 is the refractive index of the first material, and n2 is the refractive index of the second material. A good example of Fresnel reflection is provided by diamond. Diamond has a very high refractive index (e.g., 2.42). Air has a unit refractive index (e.g., 1.00). The Fresnel reflectivity of light perpendicular to the air-diamond interface is approximately 17%. The Fresnel reflectivity tends to be at a minimum at perpendicular angles and increases at grazing angles. Therefore, for diamond, at least almost 1 / 5 of the light is reflected at the air-diamond interface. As a result, the diamond shines in the light.
[0262] In the skin, melanin has a different refractive index at optical wavelengths than the surrounding tissues (e.g., the refractive index of melanin at 1064 nm is about 1.78 and the refractive index of the epidermis is about 1.35). Therefore, the normal Fresnel reflectance at the skin-melanin interface is about 2%. The basal layer at the bottom of the epidermis contains melanocytes and is therefore extremely rich in melanin. Except in pathological cases (especially dermal dark spots), the dermis directly below the basal layer is generally free of melanin. Therefore, in some embodiments, the focal area is referenced to the dermis-epidermis junction of the skin (e.g., the basal layer).
[0263] Depth of focus reference example 2
[0264] A second focal depth reference example uses a camera sensor other than an imaging (eg, confocal) aperture. FIG. 21A to FIG. 21CAn example according to some embodiments is illustrated. Fig.21A A treatment system 2100 is shown that is configured to direct and focus radiation (e.g., laser) into a target tissue. The radiation beam is provided by an optical fiber 2110 and collimated by a collimator 2112. The radiation beam is focused by an optical system and directed through the system 2100. The focused radiation beam is ultimately directed out of a window 2114 at the bottom of the system 2100. The window 2114 is configured to contact the treatment tissue so that the focal region of the focused radiation beam is within the target tissue. The system 2100 also includes a port 2116. The port allows at least a portion of the radiation from near the focal region to be directed out. Thus, the port 2116 allows signal radiation from near the focal region to be "picked up" and detected. One use of the signal radiation is a depth of focus reference to determine a reference focus position corresponding to a partially reflective interface (e.g., the surface of the window 2114).
[0265] FIG. 21A to FIG. 21C The system 2100 is illustrated with a removable reference system 2120 attached to the port 2116. According to an exemplary use of the system 2100, the removable reference system 2120 is installed prior to treatment and can be used to reliably locate the focal area relative to a known reference (e.g., a tissue surface or a window surface). Fig. 21C , signal radiation 2129 propagates substantially along optical axis 2130. Beam splitter 2132 allows at least a portion of signal radiation 2129 to be transmitted toward window reference system 2120. According to some embodiments, beam splitter substantially reflects collimated radiation beam 2134 output from collimator 2112. Signal radiation is imaged onto camera sensor 2138 (Mightex PN: SCE-B013-U) through imaging lens 2136 (e.g., Edmund Optics PN: 33-020). Measurements made using a second depth of focus reference example system are provided below to demonstrate the accuracy and usefulness of the system.
[0266] The measurement represents the position of the objective lens along the optical axis, which causes the corresponding focal area to be juxtaposed with the surface of the window. The juxtaposition of the focal area and the window surface is determined by the participant who performs the measurement. The participant is responsible for determining the position of the objective lens that makes the image of the signal radiation have the minimum size. The measurement is performed by two participants. The first participant performs all measurements numbered 1 to 3, and the second participant performs all measurements numbered 4 to 6. Measurements are performed at all 4 corners of the window surface (upper left (TL), upper right (TR), lower left (BL), lower right (BR)). The following table summarizes the measurement results.
[0267] Exemplary EMR-Based Treatment and Window Reference System
[0268]
[0269] The measurement results indicate the repeatability of the exemplary window reference system even when the minimum size of the image is determined subjectively by different participants. Although these measurements are made in part by using the judgment of human participants, in some embodiments, a controller is used to determine the image size and automatically control the focus area position. In addition, as can be inferred from the results, the parallelism of the window surface relative to one or more scan axes can be calculated from the measurements made by the window reference system. For example, one can approximate the angle between the scan axis and the window surface according to the following equation, which assumes a small angle approximation:
[0270]
[0271] Where: α is the angle between the scan axis and the window surface, in radians; Z ref,1 is the depth measured at a first location (e.g., a first corner of the window surface) in microns; Z ref,2 is the depth measured at a second location (e.g., a second corner of the window surface) in micrometers; and d 1-2 is the distance between the first position and the second position along one or more scan axes substantially perpendicular to the optical axis, in microns. FIG. 18A to FIG. 18B The feedback and treatment system 2100 requires a "pick-up" from the optical path (e.g., beam splitter 1832). According to some embodiments, there is no "pick-up".
[0272] Depth of focus reference example 3
[0273] FIG. 22A to FIG. 22C Another exemplary depth of focus reference and therapy system 2200 is shown in accordance with some embodiments. Fig.22A A treatment system 2200 is shown that is configured to direct and focus radiation (e.g., laser) into target tissue. The radiation beam is provided by an optical fiber 2210 and collimated by a collimator 2212. The radiation beam is focused by the optical system and directed through the system 2200. The focused radiation beam is ultimately directed out of a window 2214 at the bottom of the system 2200. The window 2214 is configured to contact the treatment tissue so that the focal area of the focused radiation beam is within the target tissue. The system 2200 does not contain a port or "pick-up" in the optical system.
[0274] FIG. 22B to FIG. 22CThe system 2200 is illustrated with a removable reference system 2220 attached. According to an exemplary use of the system 2200, the removable reference system 2220 is installed prior to treatment and used to reliably locate the focal region relative to a known reference (e.g., a window surface). The removable reference system 2220 is attached to the outer diameter of the collimator 2212. This allows the optical axis 2222 of the reference system 2220 to be nominally aligned with the optical axis 2224 of the treatment system. Reference radiation is generated by a reference radiation source 2226 (e.g., a diode laser Thorlabs PN: LPS-1064-APC-SP and a collimating lens [e.g., Edmund Optics PN 33-020]). The reference radiation is partially reflected by a beam splitter 2232 (e.g., a 50-50 beam splitter Thorlabs PN: BSW4R-1064) and directed along the optical axis 2222 of the reference system. The reference radiation is focused by reference objective 2233 (eg, Thorlabs PN: C240TME-1064).
[0275] In some versions, reference objective 2233 has a prescription approximately equal to the prescription of treatment objective 2234. Reference objective 2233 is located in a reference stage 2235 that translates reference objective 2233 along optical axis 2222. Reference objective 2233 directs reference radiation to a reference focal region along optical axis 2222. Thus, reference stage 2235 translates the reference focal region as well as reference objective 2233. With the reference focal region located near the surface of window 2215, some portion of the reference radiation is reflected by window 2215. A portion of the reflected reference radiation is collimated by reference objective 2233, transmitted through beam splitter 2232, and imaged onto camera sensor 2238 by imaging lens 2236. Similarly, the transmitted radiation from the collimator 2212 is focused by the treatment objective 2234, transmitted through the window 2215, a portion of the transmitted light is collimated by the reference objective 2233, transmitted through the beam splitter 2232, and imaged onto the camera sensor 2238 by the imaging lens 2236.
[0276] According to an exemplary embodiment of the system 2200, in use, the reference focal region is brought to a reference position that coincides with the outer surface of the window 2215 by translating the reference stage 2235. The reference image captured by the camera 2238 is used to determine the position where the reference focal region coincides with the outer surface of the window 2215. The reference image size will have a minimum value where the reference focal region coincides with the window 2215. At this point, the reference objective lens 2233 has a focal plane that substantially coincides with the outer surface of the window 2215. The therapeutic radiation source is then turned on, thereby generating transmitted radiation. Although in some cases, the therapeutic radiation source is operated at a lower power (e.g., 10%) than the typical power during treatment.
[0277] The transmitted radiation is focused by the treatment objective 2234 and transmitted through the window 2215. A portion of the transmitted radiation is collimated by the reference objective 2233, transmitted through the beam splitter 2232, and imaged onto the camera sensor 2238 by the imaging lens 2236. A transmission image is detected by the camera sensor 2238, which represents the width of the transmitted radiation beam at the focal plane of the reference objective 2233 (e.g., the outer surface of the window). The treatment stage 2240 translates the treatment objective 2234 along the optical axis 2224. The transmission image has a minimum size where the location of the transmission focal region coincides with the focal plane of the reference objective 2233. Although the optical axis 2222 of the reference system is nominally aligned with the optical axis of the treatment system 2224, in some forms it is advantageous for the two axes to be slightly displaced from each other. In some embodiments, a translation stage 2242 is used to displace the reference system optical axis 2222. Once the transmission focal region is positioned to coincide with the outer surface of the window, the treatment stage can be zeroed, the reference system can be removed, and treatment can be performed.
[0278] The example uses of feedback-informed EMR-based therapy described above (e.g., detection of harmful and beneficial plasma events and accurate placement of focal areas during treatment) are generally related to providing safe and effective treatment. Additional uses of feedback-informed EMR-based therapy may be related to additional goals, such as capturing and documenting tissue images to help determine a diagnosis or demonstrate positive treatment outcomes.
[0279] Tissue Imaging Examples
[0280] EMR-based treatments informed by tissue imaging feedback have a wide range of uses and benefits for dermatology and aesthetic treatments. For example, according to some embodiments, tissue imaging allows a user to accurately target a treatment site during an EMR-based treatment. Another exemplary use of tissue imaging is to provide documentation of treatment results over time (e.g., pre-treatment images and post-treatment images). According to yet other embodiments, tissue imaging is used to clarify diagnosis or treatment planning of a condition prior to treatment or endpoints during treatment. Many exemplary EMR-based skin treatments are targeted for aesthetics (e.g., related to skin appearance). In these cases, imaging the skin being treated can provide some of the most important feedback to treatment stakeholders (patients and practitioners).
[0281] Fig.23A flow chart of a method 2300 of imaging and radiation based therapy according to some embodiments is illustrated. The method 2300 begins by illuminating tissue with imaging radiation (2306). Typically, illumination of the tissue is achieved in part by using an illumination source. Illumination can be performed in a variety of ways, including: bright field illumination, where the imaging radiation is provided substantially coaxially to the imaging system; and dark field illumination, where the imaging radiation is provided substantially off-axis to the imaging system. In some embodiments, the imaging radiation is substantially monochromatic. In some other embodiments, the imaging radiation is substantially broadband (e.g., white light).
[0282] Next, an image of the view of the tissue is imaged (2310). Imaging is performed at least in part using focusing optics (e.g., an objective lens). In some cases, the view is a field of view of a focal region associated with the focusing optics. In some embodiments, imaging the image (2310) includes using a further additional optic in conjunction with the focusing optics. For example, the focusing optics can significantly collimate light from the view, and a tube lens can be used to form an image from the collimated light. The image can be formed at an image plane.
[0283] Next, the image is detected (2312). Typically, a detector is used to detect the image. Examples of detection include: photoelectric detection, confocal photoelectric detection, interference detection, and spectral detection. The detector can detect the image at the image plane. The image can be detected by an image sensor. Examples of image sensors include semiconductor charge coupled devices (CCDs), active pixel sensors in complementary metal oxide semiconductors (CMOSs), and N-type metal oxide semiconductors (NMOS). Image sensors typically output the detected image in a two-dimensional (2D) data matrix (e.g., a bitmap).
[0284] The image is then displayed (2314). Typically, the image is displayed by an electronic visual display. Examples of displays include: electroluminescent (EL) displays, liquid crystal (LC) displays, light emitting diode (LED) backlit liquid crystal (LC) displays, light emitting diode (LED) displays (e.g., organic LED (OLED) displays and active matrix organic LED (AMOLED) displays), plasma displays, and quantum dot displays. The displayed image is viewed by a designated user (e.g., a clinician). In some cases, the image is recorded and stored, for example, by controller 2419. According to some embodiments, the displayed image is used to target an area of tissue that requires treatment.
[0285] A target treatment area is then designated within the tissue (2316). In some embodiments, the target treatment area is designated based in part on the image. For example, the target treatment area (2316) can be designated based on a significant excess of pigment (e.g., dermal melanin) in a portion of the tissue as displayed in the image. In some cases, a clinician viewing the displayed image designates the target treatment area. Alternatively, in some embodiments, a controller automatically designates the target treatment area based on the image. The target treatment area is typically at least partially present in the image.
[0286] Finally, the therapeutic radiation is focused to a focal region within the treatment area (2318). Typically, the therapeutic radiation is focused using focusing optics and is configured to perform an effect within the tissue (e.g., selectively generate a thermal ionic plasma at a chromophore; achieve a cosmetic effect). In some embodiments, parameters affecting the therapeutic radiation are controlled based in part on the image. Parameters affecting treatment with therapeutic radiation are described in detail above. In some embodiments, the focal region is scanned within the target treatment area.
[0287] In some embodiments, a view is scanned from a first region of tissue to a second region. Scanning examples include: tipping / tilting a view, rotating a view, and translating a view. Further description of the relevant scanning means is described in U.S. Patent Application No. 16 / 219,809, "Electromagnetic Radiation Beam Scanning System and Method," by Dresser et al., which is incorporated herein by reference. In some embodiments, a view located at a first region overlaps a view located at a second region. In such a case, some tissues are present in both the first region and the second region. In some other embodiments, a view located at a first region does not overlap a view located at a second region. In some embodiments, the scanning of a view is achieved using feedback associated with the position of the view. For example, in some cases, a view is scanned by moving a focusing optical device using two linear stages. When located at the first region and / or the second region, feedback from an encoder present on each linear stage can be used to infer the position of the view.
[0288] A second image of a view from a second area can be imaged. Typically, imaging the second image is performed in the same manner as imaging the first image (2310), with only the location of the view differing between the two steps. Imaging is performed at least in part using focusing optics. In some cases, the view is a field of view of a focal area associated with the focusing optics. The second image can be detected. Typically, detecting the second image is performed in the same manner as detecting the first image (2312), with the only difference being that the second image is detected instead of the first image.
[0289] In some cases, the first image is stitched together with the second image into a stitched image (or mapping). The stitched image may also include additional images taken using views located at additional areas. The stitched image may be used to record a pre-treatment image of the tissue or a post-treatment image of the tissue. Any of the first image, the second image, and the stitched image may be taken before treatment and may be used to support the determination of a diagnosis, for example, by medical personnel. Similarly, any of the first image, the second image, and the stitched image may be taken during or after treatment to demonstrate the effectiveness of the treatment or to find an endpoint during treatment that may indicate the end of treatment.
[0290] See also Fig.24 , shows a schematic diagram of a system 2400 for tissue imaging and treatment according to some embodiments. The imaging and treatment system 2400 includes a focusing optics 2410. The focusing optics 2410 (e.g., an objective lens) is configured to image a view 2412 of tissue 2413. A detector 2414 is configured to detect an image 2416 formed at least in part by the focusing optics 2410. The detector 2414 communicates with a display 2417. The display is configured to display the image to a designated user (e.g., a clinician). According to some embodiments, a tube lens 2418 is used in conjunction with the focusing optics 2410 to form the image 2416. The detector 2414 communicates with a controller 2419 such that data associated with the detected image from the detector is input to the controller 2419. The focusing optics 2410 is used to deliver therapeutic radiation 2420 as well as imaging. A scanner 2422 is configured to scan the view 2412. The scanner typically scans the view in at least one dimension. In some embodiments, scanner 2422 scans the view in all three dimensions. Fig.24 , shows a scanner 2422 scanning a view 2412 from a first region 2424 to a second region 2426 of tissue 2413 .
[0291] As the scanner 2422 scans the view 2412, the focusing optical device 2410 images a first image at a first area 2424 and a second image at a second area 2426. The first image and the second image are both detected by the detector 2414. Moreover, data associated with the first detected image and the second detected image are input to the controller 2419. In some embodiments, the data associated with multiple images are stitched together by the controller 2419 to produce a stitched image (or mapping). The stitched image and / or one or more images can be recorded and stored by the controller for future review. In some embodiments, data from one or more images is used to determine a treatment area. According to some embodiments, determining the treatment area is automatically performed by the controller. In some other embodiments, determining the treatment area is manually performed by a designated user after viewing one or more images.
[0292] The therapeutic radiation 2420 is focused by the focusing optics 2410 to the focal region. Moreover, the focal region is directed to the treatment area. According to some embodiments, the scanner 2422 is configured to scan the focal region within the treatment area. Some embodiments of the system 2400 include a window 2430 placed in contact with the surface of the tissue 2413. The window 2430 can be used for several purposes, one purpose being to reference the outer surface of the tissue. Thus, the window 2430 allows the focal region to be reliably located within the tissue 2413 at a predetermined depth from the surface of the tissue 2413.
[0293] Fig.25 A stitched image (or mapping) 2500 is schematically illustrated in accordance with some embodiments. The stitched image 2500 includes a number (e.g., 9) of individual images 2510. A scan path 2520 shows the path that the view takes as it traverses the tissue. The scan path shown includes a grid pattern, but other patterns are possible (e.g., a spiral). Each individual image 2510 is taken at a point located along the scan path. The stitched image 2500 can be formed from the individual images in several ways. For example, if the position of the view is estimable for each individual image (e.g., through scanner feedback), then the stitched image 2500 can be constructed by dead reckoning calculations. Alternatively, the stitched image 2500 can be constructed using a machine vision algorithm for stitching. A first example imaging stitching software is the Hugin-Panorama photo stitcher. Hugin is hosted at http: / / hugin.Sourceforge.net The second example image stitching software is a photo synthesis tool in Adobe Photoshop. Specific individual embodiments are provided below to further explain tissue imaging in EMR treatment devices.
[0294] Tissue Imaging Example 1
[0295] FIG. 26A to FIG. 26B A schematic diagram of an example tissue imaging and treatment system 2600 is illustrated. Fig.26A A front view of system 2600 is shown. Fig.26B Shown along Fig.26A A cross-sectional view of system 2600 taken along section line BB in FIG.
[0296] System 2600 includes a fiber laser 2610. Fiber laser 2610 is configured to output therapeutic radiation. An example of a fiber laser is a Feibo 1060nm, 40W, 20Khz fiber laser from Feibo Laser Technology Co., Ltd. in Shanghai, China. The therapeutic radiation is directed to focusing optics 2620 by an optical system, which focuses the therapeutic radiation through a window 2622 to a focal area in a tissue (not shown). The optical system is configured to allow the focusing optics 2620 to be scanned in all three dimensions. This allows the focal area of the therapeutic radiation to be scanned in all three dimensions within the tissue. The scanning is accomplished by three separate stages, each responsible for a single axis. X stage 2625 scans the focusing optics on the X axis. Y stage 2626 mounted to X stage 2625 scans the focusing optics on the Y axis. Also, the Z stage mounted to the Y stage 2626 scans the focusing optics in the Z axis (e.g., generally along the optical axis of the focusing optics). An exemplary X stage is a Dover MMX 50 from Dover Motion, Inc., Bucksboro, MA, USA, controlled by an Elmo DC whistle Gold controller from Elmo Motion Controllers, Ltd., Petah Tikva, Israel. An exemplary Y stage is a Q545.140 stage controlled by an E 873 controller from Physik Instrumente LP, Auburn, MA, USA. An exemplary Z stage is a New Scale 3M-FS from New Scale Technologies, Inc., Victor, NY, USA.
[0297] The optical system includes a beam splitter 2630 configured to reflect therapeutic radiation and transmit other radiation (e.g., visible light). Thus, imaging radiation (e.g., visible light) from the tissue is imaged by the focusing optics 2620 through the beam splitter 2630. A lens assembly 2632 is positioned along the beam of the beam splitter 2630. An example of a lens assembly is a VarioOptic autofocus lens module part number: CC-39NO-250 from Corning, Inc., Corning, New York, USA. The imaging radiation is further imaged by the lens assembly and ultimately detected by a camera 2634, and more specifically, by an image sensor within the camera. An example camera is a PL-D755 from PixelLink of Ontario, Canada. The PL-D755 has an image sensor, which is a SONY IMX250 CMOS with a global shutter. In order to perform microscopic imaging of very small areas, the imaging system shown requires illumination of the tissue.
[0298] The frame 2640 is shown as having a plurality of holes 2642 therethrough. Within the holes 2642, a plurality of fiber optic bundles (not shown) are placed. In the exemplary lighting scheme, 12 fiber optic bundles contained within a 0.06" diameter stainless steel tube are placed in the holes 2642 positioned around the frame 2640. The fiber optic bundles converge into a single bundle at the distal end. The single bundle is placed in optical communication with a light source. The exemplary light source is a daylight white 6500K purchased from Fiber Optic Technologies, Inc. of Pomfret, Connecticut, USA. 38W Light Engine Part Number FTIII24015. The aperture 2642 is angled toward the window 2622 so that, when the bundle is present, light from the fiber optic bundle is directed toward the tissue. Illuminating at an angle relative to the optical axis of the focusing optics may be referred to as dark field illumination. In some embodiments, dark field illumination is advantageous because specular reflections from the window surface are not imaged through the focusing optics (as glare). In other embodiments, illumination is typically provided coaxially with the optical axis. This illumination technique may be referred to as bright field illumination. In some embodiments, bright field illumination is advantageous because it provides a greater illumination density within the field of view of the focusing optics. To demonstrate practicality, images captured using an example imaging system are described.
[0299] Fig.27A Shown by Fig.26A 2710 captured by the example system 2600 shown in B. This image captures the Air Force 1951 target. 18 images like this image 2710 are captured (2 rows of 9). These 18 images are stitched together into a stitched image 2720, which is shown in FIG. Fig.27B . The stitching was automatically performed using the photo compositing tool in Adobe Photoshop. Review of the stitched image 2720 shows that the 7th group element 6 is resolvable. The line in the 7th group element 6 is about 2.2 μm wide. Therefore, using Fig.26A With the example system 2600 shown in FIG. 2B , microscopic imaging is practical.
[0300] Additional Embodiments
[0301] In some embodiments, the repetition rate of the input laser beam can be faster than the decay rate of the plasma in the target tissue / target material. This can allow continuous (e.g., continuous in time, continuous in space, etc.) generation of plasma. The area of the treatment area / target area (e.g., the area where plasma is generated) can be controlled by changing the repetition rate of the laser beam.
[0302] Additional embodiments include alternative imaging techniques for use in conjunction with EMR-based therapy. These alternative imaging techniques include: microscopic imaging, wide-field imaging, reflectance confocal imaging, optical coherence tomography, optical coherence elasticity imaging, coherent anti-Stokes Raman spectroscopy, two-photon imaging, second harmonic generation imaging, phase conjugate imaging, photoacoustic imaging, infrared spectral imaging, and hyperspectral imaging.
[0303] Those skilled in the art will understand other features and advantages of the present invention based on the above-described embodiments. Therefore, except as indicated by the appended claims, the present invention is not limited by the content that has been specifically shown and described. The full contents of all publications and references cited herein are expressly incorporated herein by reference.
[0304] The subject matter described herein can be implemented using digital electronic circuit systems or computer software, firmware or hardware (including structural devices disclosed in this specification and their structural equivalents) or a combination thereof. The subject matter described herein can be implemented as one or more computer program products (such as tangibly implemented in an information carrier (such as implemented in a machine-readable storage device) or implemented in one or more computer programs in a propagation signal) for execution or control of the operation of the data processing device by a data processing device (such as a programmable processor, a computer, or multiple computers). Computer programs (also referred to as programs, software, software applications, or codes) can be written in any form of programming language (including: compiled language or interpreted language), and computer programs can be deployed in any form (including: as a stand-alone program or module, component, subroutine, or other unit suitable for a computing environment). A computer program does not necessarily correspond to a file. A program can be stored in a portion of a file that holds other programs or data, or in a single file dedicated to the program under discussion, or in multiple collaborative files (such as files storing one or more modules, subroutines, or partial codes). A computer program can be deployed to be executed on one computer or on multiple computers that are located at one site or distributed across multiple sites and interconnected by a communication network.
[0305] The processes and logic flows described in this specification (including the method steps of the subject matter described herein) can be performed by one or more programmable processors, which execute one or more computer programs to perform the functions of the subject matter described herein by operating on input data and generating output. The processes and logic flows can also be performed by a dedicated logic circuit system (such as an FPGA (field programmable gate array) or an ASIC (application-specific integrated circuit)), and the apparatus of the subject matter described herein can also be implemented as the dedicated logic circuit system.
[0306] Processors suitable for executing computer programs include, for example, general-purpose microprocessors and special-purpose microprocessors and any one or more processors of any kind of digital computer. In general, the processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are: a processor for executing instructions and one or more memory devices for storing instructions and data. In general, a computer will also include one or more mass storage devices (such as magnetic disks, magneto-optical disks or optical disks) for storing data, or the computer can be operatively coupled to receive data from the mass storage device or transfer data to the mass storage device or both. Information carriers suitable for implementing computer program instructions and data include all forms of non-volatile memory, including, for example, semiconductor memory devices (such as EPROM, EEPROM, and flash memory devices), magnetic disks (such as internal hard disks or removable disks), magneto-optical disks, and optical disks (CD disks and DVD disks). The processor and memory can be supplemented by a dedicated logic circuit system or can be incorporated into the dedicated logic circuit system.
[0307] To provide interaction with a user, the subject matter described herein may be implemented on a computer having: a display device, such as a CRT (cathode ray tube) or LCD (liquid crystal display) monitor, for displaying information to the user; and a keyboard and pointing device (such as a mouse or trackball) through which the user can provide input to the computer. Other types of devices may also be used to provide interaction with the user. For example, the feedback provided to the user may be any form of sensory feedback (such as visual feedback, auditory feedback, or tactile feedback), and input from the user may be received in any form including acoustic, voice, or tactile input.
[0308] The technology described herein can be implemented using one or more modules. As used herein, the term "module" refers to computing software, firmware, hardware and / or its various combinations. However, at a minimum, a module should not be interpreted as software that is not implemented on hardware, firmware or is not recorded on a non-transient processor-readable and recordable storage medium (that is, the module itself is not software). In fact, "module" will be interpreted as always including at least some physical, non-transient hardware, such as a part of a processor or a computer. Two different modules can share the same physical hardware (for example, two different modules can use the same processor and network interface). The modules described herein can be combined, integrated, separated, and / or copied to support various applications. In addition, instead of the function performed at a specific module or in addition to the function performed at a specific module, the function described as being performed at a specific module can be performed at one or more other modules and / or by one or more other devices. Further, a module can be implemented across multiple devices and / or other components that are local or remote to each other. In addition, a module can be moved from one device and added to another device and / or can be included in two devices.
[0309] The subject matter described herein may be implemented in a computing system that includes back-end components (e.g., a data server), or a computing system that includes middleware components (e.g., an application server), or a computing system that includes front-end components (e.g., a client computer with a graphical user interface or a web browser through which a user can interact with an implementation of the subject matter described herein), or a computing system that includes any combination of such back-end components, middleware components, and front-end components. The components of the system may be interconnected by digital data communication of any form or medium (e.g., a communication network). Examples of communication networks include: a local area network ("LAN") and a wide area network ("WAN"), such as the Internet.
[0310] As used herein throughout this specification and claims, approximating language may be applied to modify any quantitative representation that may be permitted to change without causing a change in the basic function associated therewith. Unless otherwise stated or apparent from the context (except that this number will not be permitted to exceed 100% of the possible value), "approximately", "substantially" or "about" may include numbers that fall within 1% of the range of the number in either direction (greater than or less than the number), or fall within 5% of the range of the number in some embodiments, or fall within 10% of the range of the number in some embodiments. Therefore, the value modified by one or more terms such as "about", "approximately" or "substantially" is not limited to the specified exact value. In at least some cases, approximate language may correspond to the precision of the instrument used to measure the value. Here and throughout the specification and claims, range restrictions may be combined and / or interchanged, unless otherwise indicated by the context or language, such a range is identified and includes all sub-ranges contained therein.
[0311] Unless expressly indicated to the contrary, the articles "a" and "an" as used herein in the specification and claims should be understood to include plural reference objects. Unless otherwise indicated or otherwise apparent from the context, if one component, more than one component, or all components of a group of components are present in a given product or process, employed in a given product or process, or otherwise related to a given product or process, then the requirement or description including "or" between one or more components of this group is deemed to be satisfied. The present disclosure includes embodiments in which exactly one component of this group is present in a given product or process, employed in a given product or process, or related to a given product or process. The present disclosure also includes embodiments in which more than one component or all components of this group of components are present in a given product or process, employed in a given product or process, or related to a given product or process. In addition, it should be understood that, unless otherwise indicated or unless it is obvious to a person of ordinary skill in the art that a contradiction or inconsistency will occur, the disclosed embodiments provide all variations, combinations and permutations, wherein one or more limitations, elements, clauses, descriptive terms, etc. from one or more of the listed claims are introduced into another claim that is subordinate to the same basic claim (or any other claim as a related one). It is contemplated that, where appropriate, all embodiments described herein can be applied to all different aspects of the disclosed embodiments. It is also contemplated that, where appropriate, any embodiment or aspect of the embodiments or aspects can be freely combined with one or more other such embodiments or aspects. Where elements are presented in a list form (e.g., in a Markush group or similar format), it should be understood that each subgroup of the elements is also disclosed, and any (multiple) elements can be removed from the group. It should be understood that, in general, where the disclosed embodiments or aspects of the disclosed embodiments are referred to as including specific elements, features, etc., certain embodiments of the disclosure or aspects of the disclosure are composed of such elements, features, etc. or are substantially composed of such elements, features, etc. For simplicity, these embodiments are not specifically described in this article with too many words in each case. It should also be understood that any embodiment or aspect of the present disclosure may be explicitly excluded in the claims, regardless of whether a specific exclusion is listed in the specification. For example, any one or more active agents, additives, ingredients, optional agents, organism types, diseases, subjects, or combinations thereof may be excluded.
[0312] In the case of a given range in this article, embodiments of the present disclosure include embodiments in which the endpoints are included, embodiments in which both endpoints are excluded, and embodiments in which one endpoint is included and the other endpoint is excluded. Unless otherwise stated, it should be assumed that both endpoints are included. In addition, it should be understood that, unless otherwise noted or apparent from the context and the understanding of a person of ordinary skill in the art, in different embodiments of the present disclosure, the value expressed as a range can assume any specific value or sub-range within the stated range in different embodiments of the present disclosure, unless otherwise clearly indicated by the context, until one-tenth of the lower limit of the range. It should also be understood that in the case of a series of numerical values stated in this article, the present disclosure includes embodiments related in a similar manner to any intermediate value or range defined by any two values in the series, and the lowest value can be regarded as a minimum value, while the maximum value can be regarded as a maximum value. As used herein, numerical values include values expressed as percentages.
[0313] It should be understood that, unless otherwise expressly stated to the contrary, in any method claimed herein that includes more than one action, the order of the actions of the method is not necessarily limited to the order in which the actions of the method are recited, but the present disclosure includes embodiments in which the order is so limited. It should also be understood that, unless otherwise stated or obvious from the context, any product or composition described herein can be considered to be "isolated".
[0314] As used herein, the terms "comprising" or "comprises" are used to refer to compositions, methods, and corresponding components thereof that are essential to the disclosed embodiments but are open to including non-specified elements, whether essential or not.
[0315] As used herein, the term "consisting essentially of" refers to the elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of the embodiment of the disclosure.
[0316] The term "consisting of" refers to compositions, methods, and corresponding parts thereof as described herein, which compositions, methods, and corresponding parts are excluded from any elements not recited in this description of that embodiment.
[0317] Although a few variations have been described in detail above, other modifications or additions are possible.
[0318] In the above description and claims, phrases such as "at least one of" or "one or more of" may appear, followed by a list of combinations of elements or features. The term "and / or" may also appear in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradictory in the context in which the phrase is used, this phrase is intended to represent any element or feature of the elements or features listed separately, or any element or feature of the narrative elements or features combined with any element or feature of other narrative elements or features. For example, the phrases "at least one of A and B", "one or more of A and B", and "A and / or B" are intended to represent "alone A, alone B, or A and B together", respectively. A similar explanation also applies to lists including three or more items. For example, the phrases "at least one of A, B, and C", "one or more of A, B, and C", and "A, B, and / or C" are intended to represent "alone A, alone B, alone C, A and B together, A and C together, B and C together, or A and B and C together", respectively. Furthermore, the term "based on" as used above and in the claims is intended to mean "based, at least in part, on" such that non-recited features or elements are also allowed.
[0319] Depending on the desired configuration, the subject matter described herein may be implemented in systems, devices, methods and / or articles. The embodiments described in the foregoing description do not represent all embodiments according to the subject matter described herein. On the contrary, these embodiments are merely some examples according to aspects related to the described subject matter. Although some variations have been described in detail above, other modifications or additions are also possible. Specifically, in addition to those features and / or variations described herein, other features and / or variations may also be provided. For example, the embodiments described above may involve various combinations and subcombinations of the disclosed features and / or combinations and subcombinations of several other features disclosed above. In addition, the logical flows depicted in the drawings and / or described herein do not necessarily require the specific order shown or the sequential order to achieve the desired results. Other embodiments may be within the scope of the following claims.
Claims
1. A system for detecting feedback of a therapeutic device, comprising: focusing optics configured to focus the electromagnetic radiation beam to a focal region located along the optical axis; a window, intersecting the optical axis, configured to contact a surface of the tissue; a stage configured to translate the focal region substantially along the optical axis; an optical detector configured to detect a width of signal radiation emitted by the electromagnetic radiation beam reflected from the surface of the window, wherein the width of the signal radiation represents a lateral width of the electromagnetic radiation beam incident on the surface of the window; and The controller is configured as: translating the focal region substantially along the optical axis using the stage; determining a reference position based on a position of the focal region corresponding to a minimum lateral width of the electromagnetic radiation beam incident on the surface of the window, wherein a portion of the focal region substantially coincides with the surface of the window; and Using the stage, the focal region is translated to a treatment position, wherein the treatment position is located a predetermined distance from the reference position along the optical axis.
2. The system of claim 1, wherein the treatment location is configured to be located within the tissue.
3. The system of claim 2, wherein the predetermined distance is configured to position the treatment location within dermal tissue.
4. The system of claim 2, wherein the electromagnetic radiation beam is configured to perform selective thermionic plasma-mediated treatment of the tissue.
5. The system of claim 1, wherein the beam of electromagnetic radiation comprises pulses having a pulse duration of at least 1 picosecond.
6. The system of claim 1, wherein the focusing optics are further configured to image the signal radiation incident on the optical detector.
7. The system of claim 1, wherein the focusing optics are further configured to focus a second electromagnetic radiation beam to a second focal region, and wherein the second electromagnetic radiation beam has at least one of the following: a wavelength which is the same as the wavelength of the beam of electromagnetic radiation; or a wavelength different from the wavelength of the beam of electromagnetic radiation; and Wherein the second electromagnetic radiation beam is configured to produce a therapeutic effect in the tissue.
8. The system of claim 1, wherein the stage is configured to translate the focal region by translating at least one of: the focusing optics, one or more optical elements, and the window.
9. The system of claim 1, wherein the focusing optics are configured to focus the electromagnetic radiation beam to the focal region with a numerical aperture (NA) in the range of 0.2 to 1.
0.
10. The system of claim 1, wherein the focusing optics are configured to focus the electromagnetic radiation beam to the focal region, a dimension of the focal region comprising at least one of: a lateral width or a length extending in the direction of the optical axis.
11. The system of claim 1, wherein the optical detector comprises at least one of: a charge coupled device (CCD) sensor or a complementary metal oxide semiconductor (CMOS) sensor.
12. The system of claim 1, further comprising: a beam scanning system configured to scan the focal region along a scanning axis to a second position, The controller is further configured to: determining a second reference position related to the second position, wherein a portion of the focus area substantially coincides with a surface of the window; and An angle between the window and a scan path is calculated based in part on the second reference position.
